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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder characterized by 
unexplained left ventricle hypertrophy associated with non-dilated ventricular chambers. 
Several genes encoding heart sarcomeric proteins have been associated to HCM, but a small 
proportion of HCM patients harbor alterations in other non-sarcomeric loci. The variable 
expression of HCM seems influenced by genetic modifier factors and new sequencing 
technologies are redefining the understanding of genotype-phenotype relationships, even if 
the interpretations of the numerous identified variants pose several challenges. We 
investigated 62 sarcomeric and non-sarcomeric genes in 41 HCM cases and in 3 HCM-
related disorders patients. We found that 82% of the patients harbored at least one rare 
nsSNV: 11% of the patients showed only sarcomere nsSNVs, 20% of cases harbored at least 
one sarcomeric nsSNV with at least a desmosomal one and 14% displayed at least one 
desmosomal nsSNV but no other sarcomere change. We reported an association between 
desmosomal variations and the pathogenesis of HCM that has not been described to date. We 
employed an integrated approach that combines multiple tools for the prediction, annotation 
and visualization of functional variants. Several different methods were employed to predict 
the functional consequences of alleles that result in amino acid substitutions, to study the 
effect of some variants over the splicing process and to investigate the impact of these 
changes respect to the evolutionary conservation. Genotype-phenotype correlations were 
carried out for inspecting the involvement of each gene in age onset and clinical variability of 
HCM. Statistical analyses revealed an inverse correlation between the number of nsSNVs and 
age at onset, and a relationship between the clinical variability and number and type of 
variants. Then, we describe the clinical, pathological, and molecular features of the novel 
LAMP2 c.453delT mutation in one of our HCM-related disorders patients affected by Danon 
disease characterized by severe hypertrophic cardiomyopathy, mild intellectual impairment 
and rapid progression to heart failure, requiring heart transplant. Immunohistochemical 
analysis of LAMP2 in the explanted heart revealed a mosaic pattern of distribution, with 
discrete clusters of either stained or unstained cardiac myocytes, the latter being more 
frequent in the septum. Interestingly, multiple foci of microscarring were found on histology 
in the Left Ventricle (LV) free wall and septum. Our findings suggest that several features 
may contribute to the early and severe cardiac phenotype in female patients affected by 
Danon disease. In conclusion, this work aims to extend the mutational spectrum of HCM and 
to contribute in defining the molecular pathogenesis and inheritance pattern(s) of this 
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condition. Besides, we delineate a specific procedure for the identification of the most likely 
pathogenetic variants for a next generation sequencing approach embodied in a clinical 
context. 
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1. INTRODUCTION 
1.1 THE HEART 
 
The heart is a central organ in the circulatory system and it is indispensable for normal 
organism homeostatis by providing a constant supply of blood to tissues, wich carries oxigen 
and nutrients and removes carbon dioxide and waste products (Cardiac Tissue Engineering: 
Principles, Materials, and Applications; Ruvinov, Sapir, Cohen, 2012). The human heart is 
situated in the protective thorax, further back to the sternum and costal cartilages, and rests 
on the superior surface of the diaphragm. The heart assumes an oblique position in the thorax, 
with two-thirds to the left of midline. The heart and great vessels are covered by the sternum 
and central part of the thoracic cage. The apex of the heart usually hidden in the 5th 
intercostal space, just medial of the midclavicular line. All four heart valves stay well 
protected behind the sternum. The sounds of the individual valves closing are best heard at 
ausculatory sites to which their sounds are transmitted. The bicuspid (mitral) valve is heard at 
the apex of the heart in the region of the 4th or 5th intercostal spaces on the left near the 
midclavicular line. The tricuspid valve can be heard along the left margin of the sternum at 
the level of the 4th or 5th intercostal space. The pulmonary valve is situated along the left 
border of the sternum in the 2nd intercostal space. The aortic valve is fixed at the 2nd 
intercostal space on the right sternal border (Handbook of Cardiac Anatomy, Physiology, and 
Devices, Second Edition, Paul A. Iaizzo Editor, 2009). 
The heart pumps blood through blood vessels and to realize that, the heart beats about 
100.000 times every day, pumping 5 liters of blood each minute. Due to the central function 
of the heart in sustaining life and normal homeostatis of the body, the insufficient ability of 
the heart to self-rigenerate after damage results in a progressive deterioration in the heart 
function.  
During this process, the heart undergoes to some structural and biochemical changes, leading 
to reduced contractility and heart failure (Cardiac Tissue Engineering: Principles, Materials, 
and Applications; Ruvinov, Sapir, Cohen, 2012). 
1.2 CARDIAC MUSCLE STRUCTURE 
 
The internal anatomy of the heart is composed by four chambers (Fig.1). The two upper 
receiving chambers are the atria and the two lower pumping chambers are the ventricles. The 
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role of the ventricle is to pump oxygenated blood into the systemic circulation to other tissues 
of the body except the alveoli of the lungs. The role of the right ventricle is to pump 
deoxygenated blood into the pulmonary circulation to the alveoli of the lungs.  
 
 
 
Figure 1. Heart structures. A. Anterior external view of the heart. B. Major internal features of the heart 
(Cardiac Tissue Engineering: Principles, Materials, and Applications; Ruvinov, Sapir, Cohen, 2012) 
 
There is one-way flow of blood through the heart; this flow is maintained by a set of four 
valves. The atrioventricular or AV valves (tricuspid and bicuspid) allow blood to flow only 
from atria to ventricles; the semilunar valves (pulmonary and aortic) allow blood to flow only 
from the ventricles out of the heart and through the great arteries (Fig.1) (Handbook of 
Cardiac Anatomy, Physiology, and Devices, Second Edition, Paul A. Iaizzo Editor, 2009).  
The wall of the heart consists of three layers: the epicardium (external), the myocardium (in 
the middle) and the endocardium (the inner layer).  
The epicardium appears transparent and it is constitutes by mesothelium and connective 
tissue that allows a smooth, slippery texture to the outermost surface of the heart. 
Myocardium is the cardiac muscle tissue and constitutes about 95% of the heart mass and is 
responsible for its pumping action. The innermost endocardium is a thin layer of endothelium 
overlying a thin layer of connective tissue. It provides a smooth lining for the chambers and 
covers the valvesof the heart (Cardiac Tissue Engineering: Principles, Materials, and 
Applications; Ruvinov, Sapir, Cohen, 2012). 
1.3 MYOCARDIUM AND THE MYOFIBRILLAR STRUCTURE 
 
The human myocardium is composed approximately by 2.5 billion cardiomyocytes (the 
muscle cells of the heart), it is possible to find these cells only in the heart and they are 
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different from the skeletal and smooth muscle cells (Cardiac Tissue Engineering: Principles, 
Materials, and Applications; Ruvinov, Sapir, Cohen, 2012). 
Cardiomyocytes are shorter than skeletal myocytes and have one centrally located nucleus, 
sometimes they have fewer nuclei (Braunwald et al.; 1971). The cardiac muscle fibers are 
shorter than skeletal muscle fibers in lenght and less circular in the transverse section. A 
tipical cardiac muscle fiber is 50-100 µm long and has a diameter of about 14 µm. Each 
muscle fiber connects to the sarcolemma (plasma membrane) with characteristic tubules (T-
tubule). At these T-tubules, the sarcolemma is connected with a large number of calcium 
channels wich permit calcium ion exchange. The flux of calcium ions into the muscle cells 
stimulates an action potential, wich allows the cells to contract. Electrical excitation of cardio 
cells leads to contraction of the heart through the process of excitation-contraction coupling 
(ECC). The second messenger, Ca2+, is essential for cardiac electrical activity and is the 
principal activator of the myofilaments (Cardiac Tissue Engineering: Principles, Materials, 
and Applications; Ruvinov, Sapir, Cohen, 2012). 
 
 
Figure 2. Cardiac muscle structure. C. Cardiac muscle fibers.The discs contain desmosomes and gap junction 
(Cardiac Tissue Engineering: Principles, Materials, and Applications; Ruvinov, Sapir, Cohen, 2012) 
 
Furthermore, the heart is composed of fibloblasts and endothelial cells. Cardiomyocytes are 
controlled by the involuntary nervous system. The myocardium assumes a unique structures, 
each fibre contains multiple cross-banded strands (called myofibrils), that fill up most of the 
cytoplasmatic space of each cardiac myocite. Each myofribil is formed by a lot of smaller 
contractile repeating structure: the sarcomere (Fig.3). Each sarcomere is defined as the 
structures bounded on each end by Z-disc, it is the site of polarity reversal of the actin 
filaments (thin filaments), as needed to interact with the bipolar myosin (thick filaments) 
(Luther, 2009). Two giant polymer proteins, titin and nebulin/nebulette, like actin, also 
overlap within and form important parts of the Z-disc (Clark et al.; 2002) (Fig.3).  
Nebulin runs along the thin filament and forms the template for thin filament assembly 
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(McElhinny et al.; 2003). A sarcomere is defined as the arrangement of contractile proteins 
that resides between two consecutive Z-disks along a myofibril. Actin filaments anchored on 
each face of a Z-disk extend for 1 mm toward the center of adjacent sarcomeres. Thick 
filaments of the protein myosin sit in the center of each sarcomere and extend toward the Z-
disks at the ends of the sarcomere.  The thick filaments are connected at their centers by a 
protein matrix referred to as the M-line (or M-disk). The 3MDa 1 lm long protein titin runs 
between the M-line and the Z-disc (Young et al.; 1998). The region of the sarcomere in 
which the myosin filaments reside is known as the A-band. The area between A-bands is 
known as the I-band; each I-band is bisected by a Z-line and is traversed by the actin thin 
filaments (Handbook of Cardiac Anatomy, Physiology, and Devices, Second Edition, Paul A. 
Iaizzo Editor, 2009). 
 
Figure 3. Striated muscle sarcomere showing its main components.Thick and thin filaments are organized into 
contractile units called sarcomeres. Thin filaments of the protein actin, a globular protein that is polymerized 
into a filament, are attached to the Z-line. Two regulatory proteins are found on the double-stranded actin thin 
filaments: tropomyosin and troponin: tropomyosin is a rod-shaped molecule that binds to actin and troponin; 
troponin, hinds myosin when it is bind to actin by fixing tropomyosin over the actin binding site (Golob et al.; 
2014)  
 
1.3.1 Thin Filament: Actin, Troponin and Tropomyosin 
 
The principle structural component of the thin filaments is a double-stranded filament of the 
globular protein actin play a role in a lot of cellular processes like cell migration, cytokinesis, 
vescicle transport and contractile force generation (Pollard et al.; 2009). Actin in mature 
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striated myofibrils had been considered as a very stable structural component (Ono, 2010). 
The thin filaments also incorporate the regulatory proteins tropomyosin (Tm) and troponin 
(Tn). Tropomyosin is a α-helical coiled-coil that contains seven consensus pseudorepeats that 
binds to seven consecutive actin subunits along the long-pitch helix of actin filaments 
(Schmidt et al.; 2015). In skeletal and cardiac muscle, calcium binding to troponin causes a 
shift in tropomyosin’s position along actin, exposing myosin binding sites and thereby 
facilitating muscle contraction (Lehman, Craig et al.; 1994). 
Troponin is a globular protein complex with three subunits: TnC, a calcium-binding subunit; 
TnI, a subunit which facilitates inhibition of muscle contraction; and TnT, a subunit that 
connects the troponin complex to tropomyosin and actin (Barnett, 2009). Tropomyosin 
molecules are aligned end to end around the helical coil of the thin filament with one Tn 
complex attached to each Tm molecule. Troponin functions to couple Ca2+concentration 
changes to azimuthal movement of tropomyosin on the thin filament. Tropomyosin’s location 
on actin controls the access of cross-bridges to the thin filaments and thus regulates the cross-
bridge cycling that drives contraction. In relaxed muscle, at low Ca2+, tropomyosin is held by 
troponin at a location that sterically blocks the binding of the myosin heads to actin-binding 
sites (Yang et al.; 2014). During muscle activation and the subsequent increase in 
myoplasmic calcium concentrations, thin filaments are switched on when Ca2+ binds to 
troponin, than tropomyosin changes its position on the actin thin filament revealing the site 
on actin required for strong myosin binding (Fig.4). Myosin can bind the actine in a manner 
to create a forceand also alters the position of tropomyosin, and full activation of the thin 
filament requires binding of both calcium and myosin (Yang et al.; 2014) (Houmeida et al.; 
2010). 
 
Figure 4. The troponin-tropomyosin complex. Tropomyosin and Troponin work together to block the myosin 
binding sites on actin. When a calcium ion bind to troponin, the troponin-tropomyosin complex moves, 
exposing myosin binding site 
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This thin filament-based mechanism for the regulation of contraction is also used for the 
control of skeletal muscle. In contrast, the activation of smooth muscle (the muscle of the 
vascular system, gut, and airways) is also calcium dependent. However in smooth muscle 
troponin is absent. The rise in calcium concentration is sensed by the cytosolic protein 
calmodulin and activation occurs via a different thick filament-based mechanism (Handbook 
of Cardiac Anatomy, Physiology, and Devices, Second Edition, Paul A. Iaizzo Editor, 2009). 
 
1.3.2 Thick Filament: The Myosin 
 
Myosins are a family of ATP-dependent molecular motor proteins responsible for force 
production and movement of muscle cells.  
Myosin is best known for its role in muscle contraction. The protein is asymmetrically shaped 
with a long alpha-helical tail and two globular head domains. These head domains bind the 
actin and uses ATP hydrolysis to generate a force to walk along the filament of actin. The 
neckdomain acts as a linker for transducing force generated by the catalytic motor domain. 
The tail domain mediates interaction with other proteins and sometimes this domain play a 
role in regulating motor activity (Fig.5). 
This results in a bipolar structure that has a bare zone in the center and the globular “head’’ 
domains of the myosin molecules projecting from each end (Handbook of Cardiac Anatomy, 
Physiology, and Devices, Second Edition, Paul A. Iaizzo Editor, 2009). 
 
 
Figure 5. Myosin is the major contractile protein involved in eukaryotic muscle contraction by "walking" along 
actin microfilaments of the sarcomere 
 
Myosins exist in different classes and the best known are: 
Myosin I: ubiquitous cellular protein involved for the adaptation response of the stereocilia in 
the inner ear. 
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Myosin II: the myosin responsible for producing muscle contraction in muscle cells. It 
contains two heavy chains, which constitute the head and tail domains and contains 4 myosin 
light chains. In muscle cells, the long coiled-coil tails of the individual myosin join together, 
forming the thick filament of the sarcomere 
Myosin III: it has been studied in vivo in the eyes of Drosophila Melanogaster where it is 
thought to play a role in phototransduction. 
Myosin V: it is involved during the transport of cargo protein like vescicles, organelles, 
mitochondria, from the center of cell to the periphery. 
Myosin VII: it is a plant-specific myosin linked to cell division. 
Myosin XI: it directs the movement of organelles in plant cells. 
1.4 THE CARDIAC ACTION POTENTIAL 
 
The normal sequence and synchronous contraction of the atria and ventricles require the rapid 
activation of groups of cardiac cells. The generation of the action potential and the regional 
differences that are observed throughout the heart are the result of the selective permeability 
of ion channels distributed on the cell membrane (Grant, 2009). 
Ion channel are fixed in the cell membrane and they have the ability to transport ions across 
the membrane. Their permeability to ions is very selective; each type of channel permits the 
passage of one or more specific ions. In excitable membranes, the three major classes of 
cation-selective ion channel are sodium, potassium and calcium. The permeability of these 
three channels is controlled by open/close gates in response to changes voltage potential. The 
potassium, sodium and calcium channels that contibute to the action potential in normal 
hearts are regulated by voltage-gated channels. At the resting membrane potential (-85 to -90 
mV for most cardiomyocytes), the majority of potassium channels are in the open state, but 
sodium channels are closed (Milnor, 1990). Opening of the voltage-gated sodium channel in 
response to a less negative cytoplasm causes a high level of sodium into the cell and is the 
basis for the initiation of an action potential. When an excitatory stimulus causes the 
membrane potential to become less negative and further away a threshold level, the 
permeability of the membrane to ions changes, the cell rapidly depolarizes and the membrane 
potential reverses transiently prior to repolarization (Fig.6) (Cardiac Electrophysiology 
Methods and Models, D.Sigg, P.A. Iaizzo, Y.F Xiao, B. He,  2010). 
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Figure 6. Major electrophysiological properties of excitable membranes.(Cardiac Electrophysiology Methods 
and Models, D.Sigg, P.A. Iaizzo, Y.F. Xiao, B. He, 2010) 
 
The cardiac action potential is composed by 5 different phases showed below (Fig.7): 
 
1. Phase 4 is stable at ≈−90 mV in normal myocardial cells. The membrane potential at the 
onset of phase 4 is more depolarized (−50 to −65 mV), undergoes slow diastolic 
depolarization, and gradually merges into phase 0. This phase is called also “resting 
potential”. 
2. Phase 0 is the phase of rapid depolarization. The membrane potential shifts into positive 
voltage range.  
3. Phase 1 is the phase of rapid repolarization. This phase detemines the potential for the next 
phase of the action potential. Epicardial cells have a prominent phase 1 and the 
shortest action potential. 
4. Phase 2 the plateau phase, is the longest phase. It is unique between excitable cells and 
marks the phase of cthe entry of calcium into the cell.  
5. Phase 3 is the phase of rapid repolarization that restoresthe membrane potential to its 
resting value. 
 
Figure 7. Action Potential: Resting (4), upstroke (0), early repolarization (1), plateau (2), and final 
repolarization. The action potential duration (APD) is approximately 200 ms (Grant et al.; 2009) (Nattel et al.; 
2006) 
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The generation of the action potential and the regional differences that are observed 
throughout the heart are the result of the selective permeability of ion channels distributed on 
the cell membrane. The electrochemical gradient determines whether an ion moves into the 
cell (depolarizing current for cations) or out of the cell (repolarizing current for cations) 
(Fig.8). Homeostasis of the intracellular ion concentrations is maintained by active and 
coupled transport processes that are linked directly or indirectly to ATP hydrolysis (Grant, 
2009). 
 
Figure 8. Major ion fluxes across cardiac plasma membrane during action potential (Cardiac Electrophysiology 
Methods and Models, D.Sigg, P.A. Iaizzo, Y.FXiao, B. He, 2010). Modified from Katz AM, Phisiology of the 
heart 2006,  and Whalley DW, Basic concepts in cellular cardiac electrophysiology, 1995) 
 
1.4.1 The Crossbridge Cycle 
 
The interaction between myosin and actin in which the globular head of the myosin molecule 
bends towards and then binds to actin, contracts, releases actin, and then initiates a new cycle 
is known as myosin-actin cycling (Fig.9). 
The myosin head domains contain an actin-binding site and an ATP hydrolysis site and 
hydrolyze ATP to ADP and phosphate (Pi). Electrical activation of the heart and contraction 
are coupled through the intracellular movement of calcium. Depolarization of the 
cardiomyocyte cell membrane during the action potential activates the L-type voltage-
dependent calcium channels in the T tubule; the subsequent influx of calcium into the cell 
then leads to the opening of ryanodine-receptor channels inthe adjacent sarcoplasmic 
reticulum with a rapid increase in cytosolic calcium (Lopes et al.; 2016). 
The binding of calcium to troponin removes the inhibition of the Tm–Tn complex on the thin 
filament. The energized myosin crossbridges can then bind to actin to the thin filament. This 
association with actin catalyzes the release of Pi and ADP, and a concomitant force-
generating conformational change of the myosin head occurs while it is bound to actin.  
The conformational change pulls the thin filament past the thick filament. At the end of the 
force-generating transition, myosin can rebind ATP, which reduces the affinity of the 
crossbridge for actin and causes cross-bridge detachment. The subsequent hydrolysis of the 
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myosin-bound ATP, in turn, reenergizes the crossbridge and prepares it for the next force-
generating cycle. The cycle continues as long as the calcium concentration is high enough to 
keep the Tm–Tn complexes from blocking the myosin-binding sites (Handbook of Cardiac 
Anatomy, Physiology, and Devices, Second Edition, Paul A. Iaizzo Editor, 2009). 
 
 
Figure 9. Crossbridge cycle: Step 1: Myosin (M) binds ATP on its globular head domain and hydrolyzes it to 
ADP and phosphate (Pi); Step 2: the energized crossbridge (M**ADP-Pi) binds to the actin thin filament. Step 
3: The release of ATP hydrolysis products ADP and Pi from the crossbridge; Step 4: ATP binds to the 
M**ADP-Pi as it completes its powerstroke causing the dissociation of myosin and actin; Thecrossbridge cycle 
continues as long as the intracellular calcium concentration is high Handbook of Cardiac Anatomy, Physiology, 
and DevicesSecond Edition, Paul A. Iaizzo Editor, 2009) 
1.5 TITIN 
 
A lot of proteins of the sarcomeric cytoskeleton are organised by specific interactions with 
the giant protein of the sarcomere, the titin, encoded by the TTN gene. Titin is the biggest 
protein of the human body (over 1.5 μm) (Kontrogianni-Konstantopoulos et al.; 2009). The 
TTN gene consists of 364 exons, located on chromosome 2q31, that produces maximally a 
4,200-kDa protein which is composed of ~38,000 amino acid residues. The size and complex 
structure of the TTN protein allows architectural support and preserves the sarcomeric 
organization during contraction, and developing passive tension during muscle stretching 
(Chaveau et al.; 2014). It also has a sensory and signaling role through the multiple TTN-
binding proteins that are organized in signaling hot spots (Gigliet al.; 2016). Single titin 
molecules extend above the entire half-sarcomeres (from Z-disc to M-lines, more than 1 mm 
in length) and contain strain-compliant (Granzier et al.; 2005). The protein is organized in 
four structural and functional regions: the N-terminal Z-line (anchor to the sarcomeric Z-
disk), the I-band (responsible for elastic properties), A-band regions (with a stabilizer role of 
the thick filament), and the C-terminal M-line extremity (overlap in antiparallel orientation 
with another C-terminal TTN molecule; modulation of TTN expression and turnover with the 
tyrosine kinase domain) (Chaveau et al.; 2014) (Fig.10). 
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Figure 10. Domain structure of titin isoforms (LeWinter et al.; 2010) 
 
The ~1.0 MDa region in the I-band consists of some immunoglobulin (Ig)-like domains in 
tandem that make up proximal (near Z-disk) and distal (near A-I junction) segments, 
interspersed by the PEVK sequence (rich in proline, glutamate, valine, and lysine residues) 
and the N2B element. The C-terminal ~2 MDa of titin is located in the A-band and is 
inextensible. It is composed of regular arrays of Ig and fibronectin type 3 (Fn3) modules 
forming the structures called so-called super-repeats.  
A-band titin may function as a molecular ruler, regulating assembly of the thick filament. 
Titin's ~250-kDa COOH-terminal region is an integral part of the M-band and contains a 
kinase domain (LeWinter et al.; 2010). 
The 364 exons of TTN undergo extensive alternative splicing to encode different isoforms. In 
cardiomyocytes, three different isoforms of titin are expressed: adult N2BA, adult N2B, and 
the fetal cardiac titin (FCT) isoforms.  
Multiple splice pathways in the I-band encoding region (~230 exons) cause the different 
proprieties of each isoform (LeWinter et al.; 2010). The first isoform is the relatively small 
~3.0 MDa isoform and it is known as N2B titin (it contains the N2B element).  
A second class also contains the N2A element, and is named N2BA titin. N2BA contains 
additional spring elements in the PEVK and tandem Ig regions and resultsin a ~3.3-3.5 MDa 
size.  
Due to the longer extensible I-band region, the N2BA titin isoform is more compliant than 
N2B titin (Fig.9). The ratio between these two isoforms is a major determinant of the 
cardiomyocyte stiffness (Hidalgo et al.; 2013) (Gigli et al.; 2016).  
The third isoform predominates in fetal-neonatal life, which contain additional elements in 
both tandem Ig and PEVK regions, resulting in a ~3.6-3.8 MDa size protein. These isoforms 
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gradually disappear during postnatal development (LeWinter et al.; 2010).  
The isoforms, N2BA and N2B are expressed 30-40 and 60-70% respectively, within the TTN 
protein in healthy adult human heart (Lahmers, 2004). A lot of different proteins bind the titin 
(Fig.11). Two N-terminal domains (Z1 and Z2) bind to small ankyrin-1 (sANK-1), a 17-kDa 
sarcoplasmic reticulum (SR) transmembrane protein (Kontrogianni-Konstantopouloset al.; 
2003). 
This interaction plays a role in organizing the sarcoplasmic reticulum around the contractile 
apparatus at the Z-disk.  
Furthermore, Z1 and Z2 interact with Tcap (telethonin), which assembles titin filaments into 
a tightly packed anti-parallel sandwich structure that is resistant to stretch (Zouet al.; 2006).  
Additional Z-disk strength is provided by titin's Z-repeats, 45-amino-acid repeats that bind α-
actininTcap also interacts with the potassium-channel subunit MinK found in T-tubules, 
which may modulate stretch-sensitive channel function (Sorimachiet al.; 1997) (Furukawa et 
al.; 2001) (LeWinter et al.; 2010). 
 
1.5.1 Titin-Binding Protein 
 
During the last years a variety of titin-binding proteins have been discovered. 
Two different proteins bind the N2B site, one is αB-crystallin, a member of the small heat 
shock protein family that functions as a molecular chaperone (Bullard et al.; 2004). A newly 
identified group of LIM proteins characterized by 4 complete LIM domains and an N-
terminal half LIM domain, FHL proteins, interacts also with N2B element (Sheikh et al.; 
2008).  
FHL-1 is found in cardiac and skeletal muscle and FHL-2 mainly in myocardium (LeWinter 
et al.; 2010). Additionally, FHL-1 interacts with members of the MAPK signaling pathways 
(Raf1, MEK1/2, and ERK2) that co-localize with N2B in the sarcomere (Sheikh et al.; 2008). 
Together, these findings suggest that N2B facilitates assembly of a signaling complex that 
triggers hypertrophy in response to non-physiological N2B strain (LeWinter et al.; 2010). 
Additionally, the N2A element binds to three homologous muscle ankyrin repeat proteins 
(MARPs): CARP, ankrd2, and DARP. MARPs participate in stress-activated pathways and 
are upregulated after mechanical or metabolic stimulus (Witt et al.; 2004). In the A-band, the 
first Ig domain of each 11-domain super-repeat interacts with myosin binding protein C 
(MYBPC3) (Freiburg et al.; 1996). 
A-band titin should be a molecular ruler, which controls assembly and length of the thick 
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filament because it provides regularly spaced binding sites for myosin and MYBPC3 
(LeWinter et al.; 2010). 
The edge of titin's M-band region (A168-170) is a binding site for muscle specific ring finger 
protein (MURF) (Witt et al.; 2005).  
MURF-1 is a sarcomere-associated protein that is an E3 ubiquitin ligase that conjugates 
ubiquitin to proteins destined for proteolysis.  
The middle of M-line titin binds FHL-2 protein. Furthermore, the protein P94 binds the C-
terminus site of titin (Kinbara et al.; 1997). 
At last, the most C-terminal domain of titincontains a binding sites for obscurin, which is 
important for M-band stability. 
 
 
Figure 11. Proteins that bind to titin (Gigli et al.; 2016) 
1.6 CARDIOMYOPATHY: AN OVERVIEW 
 
Cardiomyopathy refers to an important and heterogeneous group of related diseases of the 
heart muscle in which the myocardium is structurally and functionally abnormal such as 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right 
or left ventricular cardiomyopathy (ARVC/ALVC) and restrictive cardiomyopathy (RCM). 
Each phenotype is sub-classified into familial and non-familial forms. These conditions have 
many causes, symptoms, and treatments but the common complications can include 
mechanical and/or electrical dysfunction, heart failure and sudden cardiac death (SCD). In 
particular, undiagnosed disease (particularly in HCM and ARVC) is the major reason for 
SCD in young adults and athletes (Maron et al.; 2006) (Elliott et al.; 2008) (Maron et al.; 
1996). It is possible to divided cardiomyopathies into two big groups based on predominant 
organ involved: primary cardiomyopathies and secondary cardiomyopathies. Primary 
cardiomyopathies (genetic, non genetic and acquired) are principally characterized by 
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problems connected to heart muscle (Fig.12); secondary cardiomyopathies show pathological 
myocardial involvement as part of a large number and variety of systemic multiorgan 
disorders (Tab.1) (Maron et al.; 2006). 
 
Figure 12. Classification of primary cardiomyopathies (Maron et al.; 2006) 
 
 
Table 1. The most important common secondary cardiomyopathies (Maron et al.; 2006) 
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It is possible to divided cardiomyophaties not only in primary and secondary form, but in 
familial and non familial cardiomyophaties (Fig.13). The term familial concerns to a 
hereditary disease passes on from one generation to the next that could be caused by the same 
genetic mutation. Many familial cardiomyopathies are monogenic disorders and they can be 
sporadic when the causative mutation happens in an individual (de novo mutation) for the 
first time and it is not correlated with the family (Elliott et al.; 2008). Non-familial 
cardiomyopathies are clinically defined by the presence of a cardiomyopathy in a patient and 
the absence of disease in other family members. Futhermore some of these disease do not 
have a uniformly expression and may evolve from one category to another during their 
natural clinical course (Maron et al.; 2006) 
 
Figure 13. Classification of familial and non-familial cardiomyophaties (Elliott et al.; 2008) 
 
The panel of the American HeartAssociation (www.heart.org) has suggested that ion 
channelopathies and disorders of conduction should also be considered as cardiomyopathies. 
The Association declares that these genetic cardiovascular disorders are responsible for 
altering biophysical properties and protein structure with the effect of create a structural 
abnormal ion channel interfaces and architecture (Maron et al.; 2006). Corcern to these 
disorders, it is particularly relevant to establish a correct medical evaluation of the affects and 
their family history (Morales et al.; 2008). The first goal of family history is to know if the 
cardiomyopathy is familial, ad, if so, to identify those individuals who may be at risk. Indeed, 
practice on clinical management and genetic testing for inherited cardiomyopathies 
recommend taking a detailed family history that includes at least three generations for the 
reduced penetrance observed in some families with cardiomyopathy, clinically screening at-
risk family members, counseling patients on a possible inherited cause, and considering 
genetic testing of the most clearly affected person in the family (Ackerman et al.; 2011) 
(Hershberger et al.; 2009). Genetic testing of at-risk family members can remove the disease 
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risk (when negative) or identify those in need of clinical monitoring or intervention to 
decrease the risk of morbidity or mortality (when positive). However, because genetic testing 
for inherited cardiomyopathies is a relatively young discipline, the spectrum of pathogenic 
variants present in the population is incompletely characterized, even in well-established 
disease genes (Teekakirikul et al.; 2013). The evidence of genetic and phenotypic overlap 
among different cardiomyopathies adds other complexity (Fig.14), often resulting in stepwise 
analysis of multiple disease-specific genes when the diagnosis is not so clear. For example, 
several sarcomeric gene mutations cause both DCM and HCM and troponin I is mutated in 
hypertrophic cardiomyopathy and restrictive form of cardiomyopathy (Maron et al.; 2006). 
Improved next generation sequencing (NGS) technologies have resulted in a remarkable 
increase in speed and efficiency about cardiovascular genetic testing of a large number of 
gene simultaneously, which empowers the practice of cardiovascular genetic medicine 
(Hershberger et al.; 2013). 
 
 
Figure 14. Relationship between genes associated with cardiomyopathies and related phenotypes (Hershberger 
et al.; 2013) 
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1.7 HYPERTROPHIC CARDIOMYOPATHY: DIAGNOSIS, MANAGEMENT AND 
TREATMENT 
 
Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder, affecting 
one of every 500 adultsand it is inherited in an autosomal dominant Mendelian pattern with 
variable expressivity and age-related penetrance (Maron et al.; 2002) (Ho, 2010a). Offspring 
of an affected individual have a 50% probability of inheriting a mutation and risk for disease; 
alternatively, sporadic cases may be due to de novo mutations in the proband but absent from 
the parents (Maron et al.; 2012). Hypertrophic cardiomyopathy affects people of both 
genders and of various racial and ethnic origins and it is the most common cause of sudden 
death in young athletes in US (Teekakirikul et al.; 2012) (Maron et al., 1996) (Ho, 2010a). 
Hypertrophic cardiomyopathy is a primary genetic cardiomyopathy (Maron, 2006) 
characterized by left ventricular hypertrophy (LVH) which is usually asymmetric, with 
greater involvement of the interventricular septum than the left ventricular-free wall 
(Fig.15A-B) in the abscence of another systemic or cardiac process (Teekakirikul et al.; 
2012). Since the first description of hypertrophic cardiomyopathy (HCM) as a clinical entity 
in 1958, the disease has interestedmostlyboth clinicians and researchers for its heterogeneity 
in clinical, phenotypic expressions a variable natural progression, wich may range from 
dyspnea and/or syncope to sudden cardiac death (Baxi et al.; 2016). Heart muscle changes 
affect the electrical stability of the myocardial cells, predisposing to heart failure and/or 
arrhythmias (Dische, 1972). LVH is caused by an increase in myocyte size, but not myocyte 
number, and by a greater amount of myocardial fibrosis, which is distributed throughout the 
interstium and in discrete foci. HCM myocytes are characterized by distorted nuclei, 
disorganized myofibrils, and abnormal registration of adjoining myocytes, which combined 
with increased fibrosis, contributes to a characteristic cardiac histopathology (Fig. 15C-D).  
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Figure 15. Cardiac manifestation of HCM. A. The normal hearth, B. The HCM hearth with increased thickness 
of the walls and papillary muscle (Image A is reprinted from Wang et al.; 2010). C. The normal myocardial 
hystology, D. HCM shows misaligned nyocytes with enlarged nuclei and expanded interstitial matrix (light 
pink). E. Major contractile proteins involved in HCM (Teekakirikul et al.; 2012) 
 
Experimental data suggest that cardiac myocyte contractile function in HCM is reduced and 
that the hypertrophy is compensatory (Marian 2000) (Rust et al.; 1999). These report, in 
conjunction with myocyte disarray led to the hypothesis that tissue Doppler imaging (TDI) 
with its possibility to identify contraction and relaxation abnormalities would be more 
sensitive for the diagnosis of HCM than conventional echocardiography. This principle has 
provided by several studies in both animals and patients carrying different sarcomeric 
mutations (Nagueh et al.; 2000) (Nagueh et al.; 2001) (Ho et al.; 2002). Up to 70% of 
patients with HCM display the left ventricular outflow tract obstruction (LVOT) strongly 
associated with progression to severe symptoms of heart failure and of death (Maron et al.; 
2003). This obstruction is induced by thickening of the interventricular septum (IVS) and 
systolic anterior movement (SAM) of the mitral valve. Furthermore, hypertrophic 
cardiomyopathy can be associated with intrinsic abnormalities of the mitral valve, including 
increased mitral leaflet area, length, and laxity, as well as anterior displacement of the 
papillary muscles, which may predispose to residual systolic anterior motionand result in 
suboptimal outcome after isolated myectomy (Fig.16) (Dearani et al.; 2007) (Heric et al.; 
1995) 
In seriously symptomatic patients with obstructive HCM, despite optimal medical therapy, 
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isolated myectomy is the golden standard with excellent perioperative and long-term 
outcomes (Woo et al.; 2005) (Maron et al.; 2003) (Ommen et al.; 2005).  
 
 
 
Figure 16. Imaging of HCM. A. Transthoracic echocardiogram in the parasternal long axis view showing basal 
septal hypertrophy (yellow line). B. Transthoracic echocardiogram in the apical view showing basal septal 
hypertrophy and SAM of the mitral valve (green arrow). C. Transthoracic echocardiogram in the apical view 
with color-flow Doppler showing turbulent flow in the outflow tract (white arrow) and mitral regurgitation 
because of mitral valve SAM. D. Cardiac MRI in the apical view showing striking asymmetric basal septal 
hypertrophy (white arrow). All images are provided by Dr. Theodore Abraham, Johns Hopkins Hospital 
(Houston, 2015) 
 
 
Based on more recent, balanced overviews of patients with HCM, the annual mortality for 
patients with HCM is estimated at 1% per year (Elliott et al.; 2014) (Maron et al.; 2002) 
(Maron et al.; 2013). 
The clinical heterogeneity of HCM needs for individual treatment: 
(1) Symptom management 
(2) risk stratification for sudden cardiac death 
(3) counselling/screening, including exercise and lifestyle recommendations, family 
screening, and genetic counseling (Fig.17) 
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Figure 17. Clinical management of hypertrophic cardiomyopathy (HCM). CaChBl indicates calcium channel 
blocker; SCD, sudden cardiac death; HR, heart rate; ICD, implantable cardioverter-defibrillator; HF, heart 
failure; and CV, cardiovascular (Ho et al.; 2012b) 
 
Management in patients affected by hypertrophic cardiomyopathy is direct towards control of 
symptoms, risk stratification and prevention for SCD, screening of relatives and the correct 
theraphy (Tab. 2)  
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Table 2. Clinical manifestations of HCM and their relative theraphy. BP, blood pressure; ECG, 
electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LV, left 
ventricular; LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; SCD, 
sudden cardiac death; VT, ventricular tachycardia (Sen-Chowdhry et al.; 2016) 
 
Prophylactic pharmacological treatment in with no clinical symptoms has not been proved to 
be effective in preventing progression of disease. Beta-blockers decrease the heart rate wich 
results in a prolongation of the diastole and relaxation phase of the heart and an increase in 
passive ventricular filling. The use of Verapilim, a calcium antagonist drug, also has 
favourable effects on symptoms by improving ventricular relaxation and filling. 
Disopyramide, a negative intropic and type I-A antiarrhythmic drug, is used in patients with 
progressive heart failure symptoms with left ventricular outflow tract obstruction and it can 
decrease systolic anterior movement of the mitral valve, LVOTO, and mitral regurgitation  
(Sen-Chowdhry et al.; 2016). In patients with hypertrophic cardiomyopathy, attention to 
specific lifestyle changes can help mitigate symptoms and may reduce the risk of sudden 
cardiac death, for example, even moderately intense physical activity may lead to syncope or 
SCD. During exercise cardiac inotropy and chronotropy augmented and the systemic vascular 
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resistance (SVR) decreases without the ability to augment cardiac output because of outflow 
obstruction resulting in systemic hypoperfusion. It is recommended that patients with HCM 
should not participate in most competitive sports with the possible exception of those that 
involve low intensity (Houston, 2015) (Elliott et al.; 2014). 
 
1.7.1 Molecular genetic basis of hypertrophic cardiomyopathy 
 
Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disordeswith 
variable expressivity and penetrance, affected one of every 500 adults inherited like an 
autosomal dominant trait (Maron et al.; 1995). Jarcho and colleagues identified the genetic 
locus responsible for familial HCM in 1989 used linkage analysis of a large, 
multigenerational family to identify a portion of the long arm of chromosome 14, which 
cosegregated with incidence of disease (Jarcho et al.; 1989). The following year, Geisterfer-
Lowrance et al. identified the first HCM-causative mutation in the MYH7-encoded beta 
myosin heavy chain (Geisterfer-Lowrance et al.; 1990). Consequently, hypertrophic 
cardiomyopathy became the first cardiac disease for which a molecular genetic cause was 
determined (Ho et al.; 2015). Since the identification of the first mutation in MYH7, 
hypertrophic cardiomyopathy has been viewed like a disease of the sarcomere, with the 
typical molecular characteristics considered to result from inadequate or dysregulated force 
generation (Seidman et al.; 2001). More than 1500 mutations in any of at least 11 genes 
encoding the molecular components of the sarcomere can lead to development of HCM, with 
the majority of these found in one or only in a few families (Seidman et al.; 2011) (Ho, 
2010b) (Baxi et al.; 2016). One or more of these genetic mutations are found in up to 60% of 
individuals with a family history of HCM and 30% of those without a family history (Gersh 
et al.; 2011). Combination of more than one mutation is not rare in 6% of affected 
individuals (Ingles et al.; 2013). Mutations can be located in many genes, but the most is 
possible to find in the genes encoding sarcomeric proteins (Seidman et al.; 2011) (Tab.3) 
(Fig.18). The most commonly affected genes identified include MYBPC3 (myosin binding 
protein C, 11p11.2, 30%-40%), MYH7 (myosin heavy chain 7, 14q11.2, 20%-30%), TNNT2 
(cardiac muscle troponin, 1q32.1, 1’%), TNNI3 (troponin I type, 19q13.42, 7%), MYL2 
(myosin light chain 2, 12q24.11, 4%), MYL3 (myosin light chain 3, 3p21.31, 2%) and TPM1 
(tropomyosin 1, 15q.22.2, 1%). The resulting pathogenetic mutations might result in 
exchange of a single amino acid for another at the protein level, or result in more radical 
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truncation of a protein with insertion or deletion nucleotides.  
 
 
 
Table 3. Genes associated with HCM (Ho et al.; 2015) 
 
 
Figure 18. Main sarcomeric genes involved in HCM (Seidman et al.; 2011) 
 
The two most frequently mutated genes are MYBPC3 and MYH7, encoding the sarcomeric 
proteins cardiac myosin-binding protein C and beta myosin heavy chain (Christiaans et al.; 
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2010) (Charron et al.; 2006).  
In particularly, MYBPC3 mutations predicted to lead to more structural changes or truncation 
of the protein are frameshift mutations (mutations resulting in the insertion or deletion of ≥1 
nucleotide in the coding region of genes), non-sense mutations leading to premature 
termination of translation, or mutations affecting normal splicing of mRNA (mutations 
involving the consensus splice sites), or intronic mutations leading to cryptic abnormal splice 
sites) (Ho et al.; 2015). 
Furthermore, Mouton and colleagues affirm that it has recently been shown that MYBPH 
(myosin binding protein H, 1q32.1) functions with MYBPC3 in regulating cardiomyocyte 
contraction in response to β-adrenergic stress. Individual knockdown of either MYBPH or 
MYBPC3 had little effect on cardiomyocyte contraction (Mouton et al.; 2016).  
Therefore, given the similarity between MYBPC3 and MYBPH in sequence homology and 
structure and the important role that MYBPH plays in cardiomyocyte contraction, Mouton 
and colleagues proposed that MYBPH, like MYBPC3, might be involved in HCM 
pathogenesis but, to date, no disease-causing mutation has been found in MYBPH. They 
hypothesized that variants in MYBPH may play a role in modifying the hypertrophic 
phenotype. Mutations in the troponins, cardiac troponin T and troponin I, and α-tropomyosin 
(TPM1), are also relatively common, a total of at least 69 mutations have been identified in 
cTn subunit proteins that have been reported to be associated with HCM, including 30 in 
troponin I, and 34 in troponin T (Cheng et al.; 2016). The majority of TNNI3 mutations 
associated with the HCM phenotype are located in the C-terminal region. Almost 60% of the 
HCM-causing TNNI3 mutations occur through the substitution of a positively or negatively 
charged amino acid for a neutral or hydrophobic one (Marques et al.; 2016). Of note, 
arginine replacement occurs ~40% of the time (Willott et al.; 2010). All of the mutations are 
single nucleotide polymorphisms (SNPs or variants), and the degree of cardiac pathology 
associated with them is highly variable as is verification of their causal nature (Cheng et al.; 
2016). The HCM-associated mutations in the myosin ELC (product of MYL3 gene) are quite 
rare, but they are also linked to malignant outcomes (Huang et al.; 2015). De novo mutations 
and germlinemosaicism occurs very rarely in HCM (Rai et al.; 2009) (Cuda et al.; 1996). A 
lot of mutations correlated to HCM are private, many of the identified mutations are novel. In 
certain countries/populations, however, founder mutations have been identified and the 
haplotype analysis suggests a common ancestor. Founder mutations have been found in the 
Netherlands (Alders et al.; 2003), South Africa (Moolman-Smook et al.; 1999), Finland 
(Jääskeläinenet al.; 2004), Italy (Girolami et al.; 2006), Japan (Kubo et al.; 2005) and in the 
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Amish population of the United States (Zahka et al.; 2008). These mutations most occur in 
MYBPC3 and the majority encode a truncated protein and implies that these defects have far 
less deleterious consequences than other HCM mutations (Seidman et al.; 2011). Landstrom 
and colleagues report three missens mutations in JPH2 (Junctophilin-2) as a novel genetic 
basis for HCM (Landstrom et al.; 2009). Junctophilin-2 is involved in the calcium signaling 
apparatus of cardiomyocytes and the discovery of mutations in that gene supports as a key 
role for calcium perturbations in a pathway that culminates in the clinically expressed disease 
phenotype of hypertrophic cardiomyopathy. Two to five percent of patients with HCM harbor 
two mutations (compound or double heterozygosity) or are homozygous for a mutation 
(Force et al.; 2010) (Marian et al.; 2008) (Ingles et al.; 2005) (Olivotto et al.; 2008). It 
appears that these patients may develop a more severe clinical phenotype (Force et al.; 2010). 
Hypertrophic cardiomyopathy associated with triple sarcomere gene mutations is rare but 
often associated with adverse outcomes, including an increased risk of developing end-stage 
disease progression and high prevalence of ventricular arrhythmias. These findings support 
the theory that multiple mutations develop more significant left ventricular hypertrophy and 
require more advanced and invasive treatments such as surgical myotomy/myectomy and 
AICD (automated implantable cardioverter-defibrillator) implantation (Ingles et al.; 
2005)(Girolami et al.; 2010). Recent studies discovered the implication of several genes 
encoding components of the Z-disc (previously associated with dilated cardiomyopathy) in 
the pathogenesis of HCM like titin (TTN, 2q31.2), muscle LIM protein (MLP/CSRP, 
11p15.1), telethonin (TCAP, 17q12) and myozenin 2 (MYOZ2, 4q26) (Alcalai et al.; 2008) 
(Hayashi et al.; 2004A) (Osio et al.; 2007) (Arad et al.; 2005) (Hayashi et al.; 2004b) (Geier 
et al.; 2003). However, for some of these genes, evidence for direct pathogenicity in HCM 
has not been clearly established. The considerable variability in penetrance and expressivity 
showed by individual mutations, not only across unrelated familiesbut even within the same 
family, indicate that factors other than the sarcomere mutation itself influence clinical course 
and outcomes. If a pathogenic mutation can be identified in a family, other relatives can 
undergo predictive genetic testing to findif they have inherited the mutation, before a clinical 
diagnosis can be established. 
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1.7.2 Cardiac titin mutations and hypertrophic cardiomyopathy 
 
Titin is a giant sarcomeric protein of the human body (over 1.5 μm) that provides passive 
stiffness to cardiac myocites and stress sensitive signaling (Kontrogianni-Konstantopoulos et 
al.; 2009) (LeWinter et al.; 2014). The TTN gene consists of 364 exons, located on 
chromosome 2q31, that produces maximally a 4,200-kDa protein which is composed of 
~38,000 amino acid residues. At its N-terminus, titin is fixed in the Z-disk of the sarcomere. 
The rest of the protein is divided into an elastic I-band region, a thick filament-binding A-
band region and the M-band region where the C-terminus is embedded (LeWinter et al.; 
2013) (Fig.19A, bottom).  
The I-band region of titin is comprised of three elements:  
1) tandem Ig segments consisting of serially-linked immunoglobulin (Ig)-like domains,  
2) the PEVK segment (with high percentages of proline, glutamic acid, valine, and lysine),  
3) the N2B element with its extensible unique sequence (N2B-Us) (Fig.19A, middle) (Labeit 
et al.; 1995) (Bang et al.; 2001) (LeWinter et al.; 2013). 
This protein is encoded by a single gene but different mRNA splice pathways result in a 
distinct isoform classes. In cardiac muscle three classes are present: adult N2BA, adult N2B, 
and fetal cardiac titin (FCT) (Fig.19A middle) (Labeit et al.; 1995) (Bang et al.; 2001) 
(Greaser et al.; 2005) (LeWinter et al.; 2013). These classes differ in their I-band region; the 
rest of the molecule is largely identical. Adult cardiac muscle co-expresses N2B and N2BA 
titin at the level of the half-sarcomere (Trombitas et al.; 2001). Finally, the cardiac isoform 
novex-1 (2980kDa) and the cardiac and skeletal muscle isoform novex-2 (2980kDa) are 
nearly identical to N2B TTN, these two isoforms differ only in the incorporation of 125 or 
192 amino acid (respectively) stretches in the I-band region. Novex-3 is presented in all 
striated muscle and is the only isoform expressing the 8-kb-novex-3 exon that introduces an 
alternative terminal coding exon (Chaveau et al.; 2014). 
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Figure 19.Structure of titin in the sarcomere (A) and mechanisms for modifying titin-based passive tension (B 
and C) A. Bottom: Single titin molecules (blue and yellow) span from Z-disk (N-terminus) to M-band (C-
terminus). Middle: Composition of extensible I-band region of N2B, N2BA titin isoforms (found in adults) and 
fetal cardiac titin isoform (FCT). Red blocks are for theIg-like domains, blue, unique sequence and yellow, 
PEVK sequence. Top: Phosphorylation sites in titin’s spring region (present in all 3 isoforms) and their 
upstream signaling pathways. B. Schematic of force-extension curves of titin isoforms and effects of 
phosphorylation on passive tension. C. Schematic effect of oxidation to form cysteine disulfide crosslinks in the 
N2B region of titin (inset) and effects on passive tension. MAPK: mitogen-activated protein kinase; GC: 
guanylylcyclase; AC: anelylylcyclase; NO: nitric oxide; ET: endothelin; ANGII: angiotensin II; IP3: inositol 
triphosphate (LeWinter et al.; 2013) 
 
Most of the initially identified TTN mutations were associated with DCM (Fig.20)(LeWinter 
et al.; 2014). Altered titin isoform expression ratios have been reported in patients with heart 
disease, i.e. patients with ischemic cardiomyopathy express increased amounts of N2BA titin, 
accompanied by reduced myofibrillar stiffness (Neagoe et al.; 2002). Titin mutations are a 
rare in patients with hypertrophic cardiomyopathy but some TTN changes associated to HCM 
are distributed along the whole TTN sequence (Chaveau et al.; 2014) (Fig.21). 
 
Figure 20. Distribution of titin mutations. DCM-causing mutations are absent from the Z-disk and M-band 
region and are most prominent into the A-band region (LeWinter et al.; 2013, figure based on data from Herman 
et al.; 2012) 
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Figure 21. Distribution of the TTN variants reported along the gene. A. Approximative position and distribution 
of the known TTN mutation. B. Schematic representation of the exons encoding the main TTN isoforms . 
Variants related to purely cardiac phenotype are indicated in blue, purely skeletal muscle phenotypes in red and 
phenotypes associating with both cardiac and skeletal muscle in green (Chaveau et al.; 2014) 
 
 
Only 4 titin missense mutations associated with an HCM phenotype were described before 
the introduction of next generation sequencing (NGS) by the screening of the Z-line, the 
cardiac-specific N2B (exon 49) and the N2A domain (exon 103 and 104) (Itoh-Satoh et al.; 
2002). In 1999, Satoh and colleagues published a Z-disk missense variant, p.Arg740Leu, in a 
single patient with HCM and showed increased binding affinity to α-actinin in a yeast 2-
hybrid assay (Satoh et al.; 1999). A second missense variant, p.Ser4116Tyr, in the N2B exon 
led to enhanced TTN binding to the LIM protein FHL2 (Itoh-Satoh et al.; 2002) (Takahashi 
et al.; 2005). Two other variants in the N2A domain showed abnormal localization of CARP, 
which is known to interact with the TTN/N2A domain (Arimura et al.; 2009). 
Recently, more comprehensive sequencing studies using next generation sequencing have 
shown a very small contribution of TTN truncating variants in HCM at a range of 1.3%-4%. 
Herman and colleagues analyzed 231 patients with hypertrophic cardiomyopathy by NGS, 
and in 3 patients (1.3%) reported a truncating variant; the finding of truncating variants in the 
control population was even higher (3%) than in the HCM cohort (Herman et al.; 2012). 
Another study by Lopes and colleagues investigated 41 cardiovascular genes in 223 patients 
with HCM using NGS (Lopes et al.; 2013). They found 219 rare titin variants in 142 patients 
(63.6%). However, of the 219 individuals, 193 carried a TTN variant in addition to a likely 
disease-causing mutation in another gene. Only 30 patients carried an isolated heterozygous 
variant, with 10 patients (4% of the cohort) having a variant predicted to cause loss of 
function. This was more than the proportion reported by Herman and colleagues for HCM but 
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lower than the proportion found in their own control exome population (UK10K project)  
(Herman et al.; 2012) (Lopes et al.; 2013). Recent data demonstrate that the ongoing 
difficulties in understanding the role of TTN variants in hypertrophic cardiomyopahty are 
more supportive of titin as a possible disease-modulating factor rather than as the primary 
cause of disease (Gerull et al.; 2015). However, recent NGS studies revealed that:  
(1) TTN variants are most often associated, in the same HCM patient, with mutations in other 
sarcomeric or HCM-candidate genes (Lopes et al.; 2013), 
(2) The prevalence of isolated titin mutations predicting loss-of-function in HCM cohorts is 
between 3% and 4%, which is comparable or even lower than that of the prevalence of TTN 
truncating mutations in the normal healthy control population (Herman et al.; 2012) (Lopes 
et al.; 2013).  
Titin mutations also appear to cause arrhythmogenic right ventricular dysplasia (ARVD), a 
disease characterized by right ventricular dysfunction and ventricular arrhythmias (Taylor et 
al.; 2011). There are no functional studies for the TTN changes identified in HCM patients, 
and the informativity of cosegregation analysis in their families is limited. Therefore, the 
implication of titin mutations in the pathogenesis of hypertrophic cardiomyopathy remain 
unclear and no genotype–phenotype correlation can be established at present (Chaveau et al.; 
2014). Finally, mutations of genes encoding proteins that interact with and/or bind to titin are 
responsible for both DCM and HCM. Until now, it has been shown than pathogenetic TTN 
mutations are common in general population and one hypothesis is that these variants act like 
a phenotypic modifier concurrently to the presence of sarcomeric mutations in the 
pathogenesis of hypertrophic cardiomyopathy. Indeed, titin variants with MAF ≤ 0,05 have 
been described in patients with HCM in association with rare sarcomeric mutations (MAF ≤ 
0,01). Targeting titin as a therapeutic strategy could potentially involve manipulation of 
isoforms, post-translational modifications, and up-regulation of normal protein in patients 
with disease causing mutations (LeWinter et al.; 2014). The central role of TTN means that 
different mutations can have significantly diverse biological effects and result in different 
clinical manifestations.  
1.8 PATHOGENESIS OF HYPERTROPHIC CARDIOMYOPATHY 
 
Hypertrophic cardiomyopathy is a very common genetic heart disease present in one in 500 
in the general population and can affect people of any age but this ratio is underestimated due 
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to the lack of information regarding familial cases or asymptomatic subjects (Marques et al.; 
2016) (Mozaffarian et al.; 2016). The clinical profile of HCM is quite heterogeneous. While 
some patients exhibit severe to mild manifestations, others don’t know that they have the 
disease (Marques et al.; 2016). The initial suspicious of HCM come from a 
disomogeneousheartbeat during physical activity, family history, or an abnormal 
echocardiogram (ECG) pattern (Marian, 2010) (Maron et al.; 2012) (Maron et al.; 2013) 
(Marques et al.; 2016). Its diagnosis is based on two-dimensional echocardiography, which 
permits the detection of an asymmetric hypertrophied left ventricle chamber. Other HCM 
clinical manifestations include left ventricular hyper-contractility, cardiac insufficiency, 
ventricular fibrillation, syncope and arrhythmias. Regarding its morphological and 
histological features, left ventricle wall and ventricular septum thickening typically occurs 
(Teare, 1958) (Maron et al.; 1979) (Varnavaer et al.; 2001) (Marques et al.; 2016). The 
architecture of the hypertrophic myocardial fibers differs in shape and angle arrangement, 
leading to a chaotic environment (Maron et al.; 1981). In combination with cellular disarray, 
fibrosis with an abnormal collagen matrix is also observed (St. John Sutton et al.; 1980) 
(Shirani et al.; 2000) (Kwon et al.; 2009) (Marques et al.; 2016) (Nakamura et al.; 2016). 
Hypertrophic cardiomyopathy demonstrates age-dependent penetrance, affecting 50–80% 
and 95% of individuals by age 30 and ages 50–60, respectively. Survival to 75 years or 
beyond has been estimated in approximately 25% of an unselected HCM cohort (Force et al.; 
2010). More than 1500 mutations have been described in association this disease: pathogenic 
mutations are found in 50–60% of familial HCM and in 30-40% of apparently sporadic cases 
with no family history (Richard et al.; 2003) (Ho et al.; 2015). The 90% of pathogenic 
mutations altering physical and functional properties of proteins are missense, in which a 
single normal amino acid is exchanged for another. Missense mutations at codons conserved 
between species and/or isoforms are more likely to be pathogenic than mutations at poorly 
conserved regions. Alternatively, more radical mutations affect many amino acids in the 
protein, resulting in a very different product (i.e., frameshift), and are generally predicted to 
carry more substantial clinical consequences. Frameshift mutations are caused by insertion or 
deletion of ±1 nucleic acids in the coding region often resulting in shortened truncated 
proteins (frequently found in the MYBPC3 gene), or abnormal splicing of messenger 
ribonucleic acid (mRNA) (Maron et al.; 2012). Some genes, or some particular mutations, 
were described as associated with a high degree of sudden death; more specifically the 
mutation p.Arg403Gln that occur in the MYH7 gene is associated with increased risk of heart 
failure and sudden death (Watkins etal.; 1995) (Force et al.; el 2010) (Ho et al.; 2015). 
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Mutation in TNNT2 can cause HCM with little hypertrophy, or even normal cardiac 
morphology, both in transgenic animals (Frey et al.; 2000) and in humans (Watkins et al.; 
1995). Individuals carrying these mutations may have a high risk of malignant ventricular 
arrhythmias and sudden cardiac death (Watkins et al.; 1995) (Frey et al.; 2000). Mutations in 
MYBPC3 have been associated with incomplete penetrance, late-onset and benign course of 
the disease (Charron et al.; 1998 Erdmann et al.; 2001). By contrast, in another study, 
mutations in MYBPC3 have been associated with a more severe prognosis (Oliva-Sandoval et 
al.; 2010), underlining, again, as the genotype-phenotype correlations in HCM are quite 
variable. Similar to other sarcomeric genes, TPM1 gene mutations are also correlated with 
hypertrophic and dilated cardiomyopathy phenotypes (Thierfelder et al.; 1994) (Olson et al.; 
2001) but occur at very low frequencies (around less than 1%), as reported by large-scale 
studies (Richard et al.; 2003) (Van Driest et al.; 2003) (Marques et al.; 2016). The 
incorporation of specific mutants (A63V, K70T, D175N, and E180G) into adult 
cardiomyocytes revealed different isometric force measurements at submaximal Ca2+ 
concentrations, suggesting that HCM-related mutants would predict clinical severity 
(Michele et al.; 1999). May also occur damage to the electrical signal conduction, leading to 
arrhythmia, tachycardia and ventricular fibrillation, which may ultimately contribute to the 
development of secondary pathologies, e.g., ischemia or hypotension (Kon-No etal.; 2001) 
(Christiaans et al.; 2009) (Lan et al.; 2013) (Crocini et al.; 2016) (Marques et al.; 2016). 
Altered ion channels including at least six susceptible genes, e.g., KVLQT1, HERG, SCN5A, 
minK, MiRP1, and RyR2 play critical steps during the development of arrhythmia phenotypes 
(Keating et al.; 2001). Of note, the ryanodine channel (RyR2) triggers the release of Ca2+ 
from the sarcoplasmic reticulum to start contraction. Mutations in RyR2 lead to aberrant 
intracellular Ca2+ metabolism and Ca2+ overload that may have an involvement in 
arrhythmias (Keating et al.; 2001). Most HCM patients are heterozygous for the mutation, 
but in 3-5% of cases, patients carry two mutations in the same gene (compound heterozygous 
or homozygous) or in different genes (digenic). This is generally associated with a more 
severe phenotype with younger age of onset (often < 10 years) and more adverse events 
suggesting a gene-dosage effect (Richard et al.; 1999) (Richard et al.; 2000) (Richard et al.; 
2003) (Ho et al.; 2000) (Lekanne et al.; 2006). Like in other genetic diseases, identified 
mutations in HCM patients can be pathogenic (disease causing), silent polymorphisms, or 
unclassified variants of which the pathogenic effect is still unclear. Indeed, distinguishing 
pathogenic mutations from VUS (variants of uncertain significance), or rare non-pathogenic 
variants, has increasingly emerged as a dilemma for interpreting testing results in HCM 
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(Tester et al.; 2011) (Maron et al.; 2012). In general, the guidelines for interpreting VUS are 
currently absent, and this type of variants have frequencies estimated from 5% to 50%, 
largely dependent on the number of pathogenicity classes used to categorize mutations and 
the number of genes in the testing panel. From a human genetics perspective, there is still 
more to learn about hypertrophic cardiomyopathy. It is clear that HCM is a truly complex 
disease that can present at any age with variable hypertrophy and outflow tract obstruction, 
and it can advance in an innocuous progression, or predispose individuals to arrhythmia and 
sudden cardiac death. This clinical heterogeneity is matched by the genotypic heterogeneity 
associated with the pathogenesis of this disease. While the mutated genes that serve as the 
molecular substrates for this disease are becoming increasingly understood, the mechanistic 
link between HCM-susceptibility mutation and disease pathogenesis and expressivity remains 
a significant challenge to elucidate (Maron et al.; 2012). Genetic testing was initially possible 
only in research laboratories capable of performing linkage analysis and candidate gene 
sequencing in large, well-characterized families with obvious inherited disease. However, 
advances in contemporary DNA-sequencing methodology make gene-based diagnosis 
increasingly feasible in routine clinical practice. Faster and more affordable genetic testing 
provides a lot of opportunities to improve diagnostic certainty when evaluating patients and 
families with relatively non-specific phenotypes of cardiac hypertrophy, dilation, and 
contractile dysfunction (Ho et al.; 2015). 
1.9 SECONDARY CARDIOMYOPATHIES: PHENOCOPIES OF HYPERTROPHIC 
CARDIOMYOPATHY 
 
Secondary cardiomyopathies show pathological myocardial involvement as part of a large 
number and variety of systemic multiorgan disorders. HCM is a complex phenotype 
generally determined by mutations on sarcomeric genes but in about 50% patients with 
unexplained LVH (left ventricular hypertrophy) no mutation in sarcomeric or sarcomere-
related genes was found (van Driest et al.; 2005) (Alcalai et al.; 2008). Likewise, epigenetic 
factors, microRNAs and protein modifications such as phosphorylation, acetylation and 
glycation are expected to contribute to phenotypic expression of cardiac hypertrophy (Marian 
et al.; 2008). The discovery of mutations in these genes provided insights into clinical 
features that distinguish different histopathology and pathophysiology in cardiac hypertrophy. 
Hyperthophyc cardiomyopathy could be linked to different diseases such as metabolic 
syndromeswith pathologic vacuoles containing glycogen or intermediary metabolites (Pompe 
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disease, Anderson-Fabry disease, PRKAG2/Wolff-Parkinson-White syndrome, 
LAMP2/Danon disease), mitochondrial diseases, nucleotide repeat syndromes, congenital 
malformation syndromes (Noonan syndrome, Cardiofaciocutaneous syndrome, Cantù 
syndrome) and other diseases. Diagnostic distinction between sarcomeric HCM and its 
phenocopieshas showed the limitations of the clinical diagnosis oh HCM and emphasized the 
need to discover the important determinants of the cardiac hypertrophic responseto elucidate 
the pathogenesis of cardiac hypertrophy and deliver effective therapy. 
For example, mutations in LAMP2 are usually associated with rapid and potentially lethal 
clinical course within the first 3 decades, requiring early consideration for heart transplant 
(Maron et al.; 2009) (Maron et al.; 2010) (Maron et al.; 2012). In Fabry disease, clinical 
benefits have been attribuited to enzyme replacement theraphy with recombinant α-
galactosidase A, including regression of left ventricular hypertrophy and improbe myocardial 
function and exercise capacity (Maron et al.; 2012). Collectively, these disorders define a 
subset of unexplained hypertrophy rather than common HCM. 
 
Pompe disease (OMIM 232300): Glycogen storage disease type II, commonly reported as 
Pompe disease, is a rare autosomal recessive disorder, caused by a deficiency of the 
lysosomal acid α-glucosidase (acid maltase, GAA) enzyme, resulting in a massive lysosomal 
glycogen accumulation in cardiac and skeletal muscles. Two forms of this disease are 
considered: the infantile form, with massive cardiac hypertrophy and muscle weakness 
characterized by prominent mortality rate during the first year of life due to cardiac and/or 
respiratory failure, and the late-onset disease form, which is characterized by a progressive 
course of muscle weakness. The involvement of respiratory muscles ultimately leads to 
premature death. The difference between these two forms has been shown to originate from 
the wide variety of mutations on the GAA gene and the level of residual enzyme activity. The 
effectiveness of enzyme replacement therapy (ERT) depends on the ability of cells to 
internalize synthetically recombinant lysosomal enzymes via the mannose-6-phosphate 
receptor pathway followed by their delivery to the lysosomes, where the replacement of the 
defective enzyme with the functional enzyme occurs. Clinical studies the use of a 
recombinant analog of α-glucosidase, alglucosidasealfa (Myozyme) have shown a significant 
increase in lifetime in parallel with prominent decrease of cardiac hypertrophy, in both 
infantile and late-onset forms (Kishnani et al.; 2007) (Leviner et al.; 2015). In the last years, 
scientists developed alternative therapeutic strategies for Pompe disease: the combination of 
ERT with immune-modulatory agents such as methotrexate account for the reduction of 
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immune response against the recombinant enzyme (Joly et al.; 2014) (Leviner et al.; 2015). 
Than, pioneering experiments in GAA-KO mice have shown that the inhibition of glycogen 
synthase by either RNA interference techniques or by negatively regulating it via its signaling 
pathway both enhanced the beneficial effect of ERT, due to reduction in lysosomal glycogen 
storage. Therefore, these techniques might be considered as a novel therapeutic option for 
Pompe patients (Clayton et al.; 2014) (Leviner et al.; 2015). 
 
Anderson-Fabry disease (OMIM 301500): The Fabry disease is an X-linked lysosomal 
storage disorder resulting from a deficiency of the lysosomal enzyme β-galactosidaseA (α-
GalA) encoded by GLA gene, leading to the accumulation of globotriaosylceramide (Gb3) in 
various tissues (Nakao et al.; 1995) (Leviner et al.; 2015) (Seydelmann et al.; 2015). Absent 
or reduced enzyme activity leads to the inability to catabolize globotriaosylceramide (Gb3) 
and related glycosphingolipids, with a progressive intracellular storage of Gb3 in various 
tissues and organs and an elevated plasma concentration of lyso-Gb3 (De Francesco et al.; 
2013) (Seydelmann et al.; 2015). The intracellular accumulation of Gb3 also occurs within 
myocytes, valves and vascular endothelium of the heart (Nakao et al.; 1995) (Duro et al.; 
2014)(Seydelmann et al.; 2015). Reported incidence is about 1:40,000 worldwide 
(Seydelmann et al.; 2015), GLA is the only gene currently known to be associated with 
Fabry’s disease, spans approximately 13 kb of genomic DNA and contains seven exons, 
encoding a 429-amino acid polypeptide that includes a 31-amino acid signal peptide. 
Principal manifestations include peripheral and autonomic neuropathy, nephropathy, 
premature stroke, and white matter lesions and cardiomyopathy. More than 50% of all Fabry 
patients have a cardiac involvement (Fabry cardiomyopathy), most frequently concentric left 
ventricular hypertrophywithout LV outflow tract obstruction (Weidemann et al.; 2005) 
(Barbey et al.; 2006) (Linhart et al.; 2007) (Seydelmann et al.; 2015). Cardiomyopathy 
usually develops at a relatively advanced stage but constitutes a major cause of mortality. It 
typically manifests in middle-aged males and elderly females as cardiac hypertrophy with 
diastolic dysfunction and involvement of the conduction tissue, which eventually leads to 
conduction block and arrhythmia (Leviner et al.; 2015). Furhermore, cardiac manifestations 
are arrhythmias, chronic heart failure and small vessel disease. Malignant arrhythmias are the 
predominant cause for the substantially increased morbidity and reduced life expectancy 
(Mehta et al.; 2005) (Seydelmann et al.; 2015). The ventricular hypertrophy increases with 
disease progression. This distinguishes Fabry cardiomyopathy from idiopathic hypertrophic 
cardiomyopathy and can be used to screen Fabry patients among individuals with 
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unexplained LV hypertrophy (Monserrat et al.; 2007) (Seydelmann et al.; 2015). The end-
stage Fabry cardiomyopathy is characterized by intramural replacement fibrosis also limited 
to the basal postero-lateral wall of the LV (Moon et al.; 2003) (Weidemann et al.; 2009) 
(Seydelmann et al.; 2015). The replacement fibrosis seems to be the main cause for cardiac 
arrhythmias like bradyarrhythmias or malignant ventricular arrhythmias, both leading to a 
bad prognosis for Fabry patients (Shah et al.; 2005) (Weidemann et al.; 2005) (Takenaka et 
al.; 2008) (Seydelmann et al.; 2015). Heterozygous females typically have milder symptoms 
at a later age, but phenotypic expression in women may range from nearly asymptomatic 
throughout life to symptoms as severe as those observed in males with the classical 
phenotype. The most common instrument to screen for Fabry cardiomyopathy is 
echocardiography, which is highly available and easily applicable. A cardiologist together 
with the other involved disciplines should define the indication for enzyme replacement 
therapy that has been approved since 2001 (Leviner et al.; 2015).While substrate 
manipulation and supporting care includingmedications, pacemaker/defibrillators, dialysis, 
and pain control are part of the therapeutic arsenal, ERT revolutionized the natural history of 
this disease, in particular when initiated before the occurrence of irreversible organ damage. 
Before and during ERT it is important to initiate additional therapy in almost every Fabry 
patient: novel approaches are developed to potentiate the effect of ERT.A recent study by 
Lukas and his groupdiscovered two new drugs that might be potential enhancers of 
pharmacological chaperones. The first is the expectorant ambroxol, especially in 
combinationwith migalastat, could raise α-Gal A levels in a cell free thermal denaturation test. 
The second, the PPAR-γagonist-rosiglitazone was also tested in a similar modal and showed 
promising results, especially in combination with migalastat (Leviner et al.; 2015) (Lukas et 
al.; 2015). 
 
PRKAG2/Wolff-Parkinson-White syndrome (OMIM 144200): Molecular studies of 
patients characterized by hypertrophic cardiomyopathy but without sarcomere-protein gene 
defects have led to the identification of other genetic causes of cardiac hypertrophy, including 
mutations in PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2)(Gollob 
et al.; 2001) (Arad et al.; 2002a) (Arad et al.; 2005). 
PRKAG2 encodes for γ2 subunit of AMPK (AMP activated protein kinase), a highly 
conserved heterotrimeric enzyme that is expressed in most mammalian tissues, including 
heart muscle. In humans PRKAG2 missense mutations cause glycogen-storage 
cardiomyopathy: studies both humans and animal models have demonstrated that these 
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mutations in the γ subunit lead to constitutive activation of PRKAG2. The alteration of 
PRKAG2 leads to altered glycogen metabolism and to dramatic accumulation of cardiac 
glycogen (Arad et al.; 2005). PRKAG2 mutations cause myocite hypertrophy by stimulating 
glycogen-filled vacuoles but cause neither myocite disarray nor interstitial fibrosis, which 
typically happen with defects of sarcomere-protein genes (Yeh et al.; 1980) (Sim et al.; 
1988) (Arad et al.; 2007). 
Whether activated AMPL also triggers other pathways that many contribute to the increase in 
cardiac mass or electrophysiological abnormalities is unknown (Arad et al.; 2005). These 
biochemical studies suggest mechanism by which PRAKG2 missense mutations determine 
AMPK activity. Under normal physiological condition, the heart has abundant ATP and 
nearly absent AMP. Under these conditions, high ATP levels inhibit AMPK. AMPK carryng 
PRKAG2 mutations has decreased affinity for ATP, and increasing baseline AMPKactivity. 
AMPK appears to have a role in regulating Akt1-indiced hypertrophy in neonatal 
cardiomyocitesbut the role of AMPL in cardiac hypertrophy remains unknown (Chan et al.; 
2004) (Arad et al.; 2007) 
 
Danon disease (DD, OMIM 300257): It is a rare monogenic metabolic X-linked disorder 
characterized by early-onset cardiomyopathy with hypertrophic or dilated phenotype 
(frequently responsible for fatal outcome), intellectual disability, and proximal myopathy 
(Danon et al.; 1981) (Bottillo et al.; 2016c). The exact prevalence of DD is unknown; 
however, it has been reported in 1-6% of patients with unexplained left ventricle hypertrophy 
(Charron et al.; 2004) (Arad et al.; 2005) (Yang et al.; 2005) (Hedberg et al.; 2015) (Bottillo 
et al.; 2016c) and in up to 17% of patients with LVH and other features such as elevated 
serum creatine kinase (CK) or Wolff-Parkinson-White (WPW) syndrome (Arad et al.; 2005) 
(Hedberg et al.; 2015) (Bottillo et al.; 2016c). 
DD is caused by LAMP2 (lysosome-associated membrane protein 2) defects which coats the 
inner surface of the lysosomal membrane and is supposed to act as a receptor for proteins to 
be imported and degraded within lysosomes in chaperone-mediated autophagy (Eskelinen et 
al.; 2002) (Bottillo et al.; 2016c). 
The lysosomes fail to fuse with autophagosomes and the cell is left with undegraded contents 
such as protein aggregates, malfunctional organelles, and old glycogen. For this reason, the 
disease was originally named Pompe with normal acid maltase (Leviner et al.; 2015). Danon 
disease is an example of primary failure of autophagy. It is now estimates that secondary 
impairment of autophagy also contributes to the pathophysiology of other lysosomal storage 
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diseases by the accumulation of toxic protein aggregates and defective mitochondria (Choi et 
al.; 2013) (Leviner et al.; 2015). 
LAMP2is located on chromosome Xq24, and its open reading frame consists of 1233 
nucleotides spanning nine exons and encoding 410 amino acids (Nishino et al.; 2000) 
(Bottillo et al.; 2016c). Exon 9 undergoes alternative splicing generating three splice 
isoforms (LAMP2A, LAMP2B, and LAMP2C) that differ in the transmembrane and 
cytoplasmic domains but have identical luminal domains (Eskelinen et al.; 2002) (Bottillo et 
al.; 2016c). LAMP2B isoform is mainly expressed in heart, skeletal muscle, and brain (the 
three “target tissues” of DD) (Di Mauro et al.; 2007) (Bottillo et al.; 2016c) while isoforms 
LAMP2A and LAMP2C are nearly ubiquitous (Konecki et al.; 2005) (Bottillo et al.; 2016c). 
To date, more than 100 genetically proven cases of DD have been reported, and most of the 
mutations are small deletions/insertions, nonsense, or splicing alterations (Cheng et al.; 2012) 
(Majer et al.; 2014) (Bottillo et al.; 2016c). 
Over several years, the heart progresses to the hypokinetic stage and develops severe heart 
failure leading to death unless heart transplantation takes place (Leviner et al.; 2015). 
Clinical manifestations are variable but normally more severe in males due to the X-linked 
dominance (Boucek et al.; 2011) (Bottillo et al.; 2016c). Typically, a teenage boy has rapidly 
progressive hypertrophy, which may reach big dimensions and be associated with Wolff-
Parkinson-White syndrome and arrhythmia (Arad et al.; 2005) (Leviner et al.; 2015). 
However, early-onset cases with unfavorable prognosis have been rarely described in females 
(Yang et al.; 2005) (Maron et al.; 2009) (Kim et al.; 2010) (Dara et al.; 2011) (Miani et al.; 
2012) (Hedberg et al.; 2015) (Bottillo et al.; 2016c). Male patients also have transaminase 
elevation without clinically significant liver disease (Arad et al.; 2005). These are believed to 
be caused mainly by an unfavorable skewing of X-chromosome inactivation (XCI) in the 
cardiac tissue (Fanin et al.; 2006) (Majer et al.; 2014) (Hedberg et al.; 2015) (Bottillo et al.; 
2016c). Electrophysiological abnormalities follow but may precede the development of 
cardiomyopathy. Because the stress of pregnancy and labor may lead to heart failure, some 
cases are wrongly diagnosed as peripartum cardiomyopathy, and correct diagnosis is reached 
only after the development of a typical disease in a male offspring (D’Souza etal.; 2014) 
(Leviner et al.; 2015). A lot of knowledge needs to be learned about the process of autophagy, 
the modification of the processes triggering autophagy may help modify the course of this 
lethal disease, while a targeted protein therapy would facilitate the restoration of the 
lysosomal function in Danon disease (Leviner et al.; 2015).  
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Mitochondrial diseases: Primary mitochondrial respiratory chain diseases are systemic 
disorders caused by sporadic or inherited mutations in nuclear or mitochondrial DNA 
(mtDNA). Their main unifying feature is an alteration in energy homeostasis caused by 
decreased ATP production (Giordano et al.; 2013). The main tissues with high-energy 
requirements involved in these diseases are brain, skeletal muscle, and heart. The 
presentation of mitochondrial DNA defects is more variable and age-dependent, related to 
tissue distribution of defective mitochondria, mutation load, and mitochondrial aging 
(Holmgren et al.; 2003) (Scaglia et al.; 2004) (Leviner et al.; 2015). Organ dysfunction is 
caused by energy deficiency, oxygen radical damage, and proapoptotic signaling by the 
damaged mitochondria. 
According with the literature, cardiac involvement is reported in about 20% to 25% of 
patients with mitochondrial disorders (Holmgren et al.; 2003) (Scaglia et al.; 2004) 
(Limongelli et al.; 2010) (Giordano et al.; 2013). Cardiac manifestations include 
cardiomyopathies that variably affect the patients' clinical outcome (Berardo et al.; 2011) 
(Giordano et al.; 2013). The most frequently reported phenotype is hypertrophic 
cardiomyopathy often caused by mutations in nuclear genes that affect the activities of the 
complexes of the mitochondrial respiratory chain (Antonicka et al.; 2003) (Haack et al.; 
2010) (Gotz et al.; 2011) (Ghezzi et al.; 2012) (Giordano et al.; 2013). However, a 
substantial proportion of cases remain genetically undiagnosed. This is the case of 
mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS, OMIM 
540000) (Limongelli et al.; 2010) (Haack et al.; 2010) (Berardo et al.; 2011) (Gotz et al.; 
2011) (Bated et al.; 2012) (Ghezzi et al.; 2012) (Hollingsworth et al.; 2012) (Giordano et al.; 
2013), caused by heteroplasmic mutations (coexistence of wild-type and mutated mtDNA 
molecules in the same cell) in the mitochondrial gene MTTL1, coding for leucine (UUR) 
tRNA. A recent study conducted by Hollingsworthand colleagues, showed that cardiac 
hypertrophy is a constant feature in patients with this point mutation m.3243ANG in 
MTTL1gene (Hollingsworth et al.; 2012). 
Furthermore, Taylor and colleagues described two families with HCM associated with a 
homoplasmic A4300G mutation in the mt-tRNAIlegene. In both families, the clinical traits 
and associated histochemical and biochemical abnormatilies were confined to the heart. This 
group studied the cardiac tissue of affected individuals which revealed not only severely 
decreased respiratory chain activity but also very low steady state levels of mt-tRNAIle 
(Taylor et al.; 2003). The mutation affects a base pair in the secondary structure of mt-
tRNAIle in a region of the gene that shows high evolutionary conservation. There was a 
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mildly asymmetric pattern of LV hypertrophy, with some patients showing a prominent 
thickening of the posterior wall and others of the ventricular septum (Taylor et al.; 2003). 
An othermithocondrial disease often associated with cardiac hypertrophy is Kearns–Sayre 
syndrome (KSS, OMIM 530000). The typical phenotype of KSS includes progressive 
external ophthalmoplegia, pigmentary retinopathy, cardiac conduction defects and less 
commonly cardiac hypertrophy (Ashizawa et al.; 2001) (Marian et al.; 2008). L-Carnitine 
deficiency, caused by mutations in chromosomal genes encoding solute carrier family 22, 
member 5 (SLC22A5) or OCTN2 transporter, could manifest as either concentric or eccentric 
cardiac hypertrophy (Guertl et al.; 2000) (Marian et al.; 2008). Similarly, mutations in 
mitochondrial carnitine palmitoyltransferaseI (CATI) and translocase (SLC25A20) are also 
associated with cardiac hypertrophy and heart failure (Kelly et al.; 1994) (Guertl et al.; 2000) 
(Marian et al.; 2008). 
In general, a muscle biopsy may be useful to confirm the clinical suspicion, although a 
mitochondrial etiology cannot be excluded based on negative histology, the natural history of 
isolated mitochondrial cardiomyopathies is often characterized by a rapid progression to 
congestive heart failure, especially in male patients (Taylor et al.; 2003) (Perli et al.; 2012) 
(Giordano et al.; 2013). 
 
Nucleotide repeat syndromes: Cardiac involvement is a major determinant of morbidity and 
mortality in triplet repeat syndromes (Korade-Mirnics et al.; 1998) (Cummings et al.; 2000) 
(Marian et al.; 2008). An example of hypertrophic cardiomyopathy phenocopiesis this class 
of neuromuscular disorders caused by the expansion of the trinucleotide repeats in various 
genes, such asmyotonic dystrophy type 1 (DM1, OMIM 160900), Huntington’s disease (HD, 
OMIM 143100) and fragile site syndromes (Cumming et al.; 2000) (Marian et al.; 2008). 
The common form of myotonic dystrophy is caused by the expansion of GC-rich triplet 
repeats in the 3’-untranslated region of DMPK, which encodes myotonicdystrophy protein 
kinase. Cardiac hypertrophy, often diagnosed as HCM, and conduction defect are the 
prominent clinical features due to progressive degeneration of muscles and myotonia 
(Korade-Mirnics et al.; 1998) (Marian et al.; 2008). Cardiac hypertrophy or dilatation also 
occurs in patients with Friedreich’s ataxia (FRDA, OMIM 229300), which is caused by the 
expansion of GAA repeat sequences in the FRDA gene (Palau, 2001) (Marian et al.; 2008). 
The severity of clinical manifestations of triplet repeat syndromes correlates with the size of 
the repeats (Bit-Avragim et al.; 2001) (Marian et al.; 2008). 
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FHL1-related diseases: Severe left ventricular diastolic dysfunction (LVDD) in individuals 
with hypertrophic cardiomyopathy has been associated with poor exercise tolerance and 
prognosis in both adults and children with the disease (Matsumura et al.; 2002) (McMahonet 
al.; 2004) (Harris et al.; 2006) (Efthimiadis et al.; 2007) (Kubo et al.; 2007) (Biagini et al.; 
2009) (Maskatia et al.; 2012) (Hartmannova et al.; 2013). Severe LVDD may occur as an 
initial manifestation of HCM with limited LV hypertrophy, or it may represent advanced 
disease, an alternative to end-stage dilated HCM (Harris et al.; 2006) (Hartmannova et al.; 
2013). Recently, Hartmannova and colleagues report a novel mutation of FHL1 c.647_648 
insTencoding four-and-a-half LIM domain protein 1 (FHL1) in 3 hemizygous males on a 
large family with isolated X-linked HCM with severe LVDD. Mild cardiac involvement in 
heterozygous females included asymptomatic abnormalities of ECGF with a modest increase 
in LV mass since the sixth decennium and 1 case of apical HCM in ninth decennium. More 
than 30 mutations of FHL1 have been associated with 5 different X-linked myopathies: 
reducing body myopathy (OMIM 300718), scapuloperoneal myopathy (OMIM 300695), X-
linked myopathy with postural muscle atrophy (OMIM 300696), rigid spine syndrome, and 
Emery-Dreifuss muscular distrophy (OMIM 310300) with a variable cardiac involvement 
presenting as dilated or HCM (Windpassingeret al.; 2008) (Gueneau et al.; 2009)  
(Knoblauchet al.; 2010) (Shathasivamet al.; 2010) (Cowling et al.; 2011) (Hartmannova et 
al.; 2013) 
 
Noonan syndrome (NS, OMIM 163950): Noonan syndrome is probably the most common 
cause of HCM phenocopy in children. It is an autosomal dominant condition with a variable 
phenotype comprising short stature, congenital heart defects and minor facial anomalies 
(Noonan, 1968) (Jongmans et al.; 2005). Its prevalence has not been determined accurately to 
date, most autohors cite thefigure of 1 in 1000-2500 live births but that estimate is not based 
on a population study (Nora et al.; 1974) (Tartaglia et al.; 2010). NS is a Mendelian trait and, 
typical for that genetic mechanism, 1/3 to 1/2 of cases arise from spontaneous mutations 
(Tartaglia et al.; 2010). Thus far, seven genes (PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, 
MEK1 and RIT1) have been causally related to this disorder (Tartaglia et al.; 2010) (Aoki et 
al.; 2013). 
The main facial findings of NS are hypertelorism with down-slanting palpebral fissures, 
ptosis, and low-set posteriorly angulated ears with a thickened helix. The cardiovascular 
defects most commonly associated with this condition are pulmonary stenosis and 
hypertrophic cardiomyopathy. Other manifestations are webbed neck, chest deformity, mild 
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mental retardation, cryptorchidism, feeding difficulties, bleeding diathesis, and lymphatic 
dysplasia (Jongmans et al.; 2005). 
 
Cardiofaciocutaneous syndrome (CFCS, OMIM 115150): It is a rare, sporadic, multiple 
congenital anomalies/mental retardation syndrome characterized by failure to thrive, severe 
feeding problems, developmental delay, reduced growth, distinctive dysmorphic facial 
features, abnormalities of the skin, gastrointestinal tract and central nervous system, and 
cardiac defects (Reynolds et al.; 1986) (Roberts et al.; 2006) (Tartaglia et al.; 2010). CFCS is 
genetically heterogeneous, with mutations in the KRAS, BRAF, MEK1 and MEK2 genes 
occurring in approximately 60-90% of affected individuals (Narumi et al.; 2007) (Niihori et 
al.; 2006) (Rodriguez-Viciana et al.; 2006) (Nava et al.; 2007) (Schulz et al.; 2008) 
(Tartaglia et al.; 2010). CFCS has considerable clinical overlap with NS, and “borderline” 
cases are commonly observed, which justified the long debated question of whether it was a 
separate nosologic entity or an extreme phenotype/variant of NS (Wieczorek etal.; 1997) 
(Fryer et al.; 1991) (Neri et al.; 1991) (Tartaglia et al.; 2010). 
Recurrent facial/head features include relative/absolute macrocephaly, which is usually 
associated with high forehead, bitemporal narrowing and facial dysmorphia that is coarser 
compared to NS. The cutaneous involvement includes dry and hyperkeratotic skin (face, arms 
and legs), ichthyosis, eczema, sparse, friable and curly hair, absent/sparse eyebrows and 
eyelashes, pigmentary changes (such as café-au-lait spots, naevi or lentigines) and 
hemangiomata. Heart defects occur in the majority of affected individuals and consist of 
pulmonic stenosis most commonly, HCM and septal defects (Roberts et al.; 2006) (Tartaglia 
et al.; 2010).  
 
Costello syndrome (CS, OMIM 218040): This disorder was originally described in 1971 
and delineated for the second time in 1977 by the same author. It is characterized by prenatal 
overgrowth followed by postnatal feeding difficulties and severe failure to thrive, distinctive 
coarse facial features, mental retardation, short stature, cardiac defects (most commonly 
hypertrophic cardiomyopathy, septal defects, valve thickening and/or dysplasia, and 
arrhythmias), skin and musculoskeletal abnormalities (Costello, 1971) (Costello, 1977) 
(Hennekam, 2003) (Zampino et al.; 2007). By using a candidate gene approach, Aoki and 
colleagues showed that germline heterozygous missense mutations in the v-Ha-ras Harvey rat 
sarcoma viral oncogene homolog (HRAS) protooncogene cause this syndrome. According to 
the available data, activating HRAS mutations have been identified in approximately 85% of 
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subjects with a clinical diagnosis of CS (Aoki et al., 2005)(Estep et al.; 2006)(Gripp et al.; 
2006)(Kerr et al.; 2006) (Zampino et al.; 2007). It is an autosomal dominant disorders and 
due to the severely reduced fitness associated with the disorder, CS almost invariably arises 
sporadically from a de novo mutation. Advanced paternal age and increased paternal–
maternal age difference has been documented in CS, suggesting that paternal germline 
mutations are the origin of disease (Lurie, 1994). 
The diagnosis of CS can be difficult and uncertain in the neonatal and infancy periods due to 
phenotypic overlap with cardiofaciocutaneous syndrome and Noonan syndrome.  
 
Cantù syndrome (OMIM 239850): Cantú syndrome is a rare condition characterized by 
congenital hypertrichosis, neonatal macrosomia, a distinct osteochondrodysplasia, and 
cardiomegaly. Cantù et al described a brother and sister and 2 sporadic cases with a 
syndrome consisting of generalized congenital hypertrichosis, macrosomy at birth, narrow 
thorax, cardiomegaly, wide ribs, platyspondyly, hypoplastic ischiopubic branches, small 
obturator foramen, bilateral coxavalga, enlarged medullary canal, Erlenmeyer-flask-like long 
bones, and generalized osteopenia (Cantù et al.; 1982). Notably, cardiac manifestations such 
as patent ductus arteriosus, ventricular hypertrophy, pulmonary hypertension, and pericardial 
effusions are present in ~80% of cases (Lazalde et al.; 2000) (Grange et al.; 2006) (Scurr et 
al.; 2011) (Van Bon et al.; 2012). Autosomal recessive inheritance of Cantu syndrome had 
been suggested but Lazalde and colleagues reported a Mexican family affected by Cantù 
syndrome with autosomal recessive inheritance. 
Van Bon et al identified heterozygosity for 4 different missense mutations in the ABCC9 
gene and they proposed that this syndrome be added to the list of potassium channelopathies 
with potential therapeutic options. The protein encoded by this gene is a member of the 
superfamily of ATP-binding cassette (ABC) transportersand encodes the channel regulator 
SUR2, which contains TMD1 and TMD2, an N-terminal domain (TMD0), and two 
nucleotide-binding folds (NBF1 and NBF2), comprising Walker A and Walker B nucleotide-
binding motifs and other conserved sequences (Higgins et al.; 2001) (Nichols et al.; 2006) 
(Van Bon et al.; 2012). Alternative RNA splicing of the terminal exon of ABCC9 produces 
two SUR2 isoforms: SUR2A, predominantly expressed in cardiac and skeletal muscle cells, 
and SUR2B insmooth muscle (Brian et al.; 2007) (Van Bon et al.; 2012). The protein SUR2 
is located in a cluster of genes on chromosome 12p12.1 with KCNJ8, suggesting co-
regulation at the gene level (Flagg et al.; 2010) (Van Bon et al.; 2012). A similar situation is 
observed for KCNJ11 and SUR1, which are also located in a cluster of geneson chromosome 
46 
 
11p15.1. The chromosome 12 cluster-genes encoded KATP channel functions primarily in 
heart, skeletal, and smooth muscle, the chromosome 11 cluster-genes encoded KATP channel 
shows a predominant role in the neuroendocrine system, and mutations in these genes may 
lead to hyperinsulinemic hypoglycemia and neonatal diabetes (van Bon et al.; 2012). KATP 
channels is responsible for the intracellular changes in the ADP/ATP ratio, thereby linking 
the metabolic state of the cell to its membrane potential (Nichols et al.; 2006) (Bryan et al.; 
2007) (de Wet et al.; 2010) (Van Bon et al.; 2012). 
Absence of sarcomeric KATP channels significantly impairs the myocyte’s ability to 
properly distribute Ca2+, decreasing sensitivity to sympathetic nerve signals and 
predisposingthe patients to arrhythmia and sudden death (Zingman et al.; 2002). 
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2. AIM OF THESTUDY 
 
Hypertrophic cardiomyopathy is an inherited disease of the heart muscle characterized by a 
relevant heterogeneity of both morphological and clinical features. Considering the extreme 
genetic heterogeneity of the disease and the cost of genetic testing, several attempts were 
made to identify the clinical predictors of an underlying mutation. For this reason, despite the 
growing knowledge on its genetic basis, the establishment of a more precise genotype-
phenotype correlation has been difficult to achieve.  
The born of next generation sequencing technology has greatly accelerated the study of the 
molecular basis of genetic diseases, including cardiomyopathies, with important 
consequences both in clinical practice and scientific research. To date, the target sequencing 
(TS) is the most widely used approach in genetic and clinical tests, which has already been 
applied for the diagnosis of hereditary cardiovascular conditions as well as of other diseases 
may represent a suitable tool. Targeted gene panels were shown to generate results with 
analytical quality identical to Sanger sequencing, and to have the advantage of being faster 
and cheaper with better coverage and sensitivity than that used in more expanded analyses. 
However, the emergence of next generation sequencing platforms imposes increasing 
demands on statistical methods and bioinformatic tools for the analysis and the management 
of the huge amounts of data generated by these technologies. 
The main purpose of the present study was to develop an informative genetic testing for 
patients affected by hypertrophic cardiomyopathy. For this reasons 44 italian HCM-patients 
were selected from San Camillo-Forlanini Hospital (Rome) and they were analyzed by two 
custom NGS panels: the first panel was designed to analyze coding, intronic junctions and 
UTR sequences of 62 sarcomeric and non-sarcomeric genes related to cardiomyopathies; the 
second panel was developed to analyze coding, intronic junctions and UTR sequences of 
Titin gene, a locus that could act as a genetic modifier in HCM.  
The second aim of this study was the analysis of genotype-phenotype correlations in HCM; 
these results could be a starting point for delineating the contribution of each analysed gene 
in the onset and clinical variability of HCM. 
Finally, the third purpose of this study was the investigation of patients affected by HCM-
related diseases, by molecular deepening and an exhaustive literature review. 
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3. MATERIALS AND METHODS 
3.1 PATIENT 
 
Forty-four adults and unrelated patients were selected from those attending an outpatient 
hospital service dedicated to the diagnosis and management of HCM. Three patients 
displayed HCM associated with a syndromic phenotype: case 10, 24 and 27 were respectively 
affected by a mild form of Fabry's disease, by Cantù's syndrome and by Danon's disease. All 
patients underwent clinical history registration, physical examination, electrocardiography, 
echocardiography, cardiopulmonary exercise test coupled with ambulatory ECG monitoring. 
Thirty-two out of 44 patients were evaluated by cardiac magnetic resonance (CMRI). 
Diagnostic criteria for HCM was defined in adults by a maximal left ventricular wall 
thickness ≥13 mm on echocardiography, in the absence of other loading conditions (Klues et 
al.; 1995). Family history of sudden cardiac death, syncope episodes and the presence of 
Non-Sustained Ventricular Tachycardia (NSTV) were defined as described by O'Mahony et 
al. (2014). Electrocardiographic changes that were considered of clinical significance 
included abnormal Q waves (0.04 s or 25% depth of an R-wave), LVH (voltage criteria), and 
marked repolarization changes (e.g. T-wave inversion in at least 2 leads). The QT interval 
corrected for heart rate was calculated using the Bazett's formula (QTc (ms) = QT / - RR, 
where RR is the RR interval measured in seconds). Familial HCM cases were defined if at 
least one additional affected family member with HCM, or one case of sudden cardiac death 
was present in the pedigree. From every patients, genomic DNA was extracted from 
peripheral blood by Maxwell® 16 Blood DNA Purification Kit (Promega). All patients gave 
informed consent for the DNA analyses, which was approved by local ethic committees in 
accordance with the principles of the Declaration of Helsinki. Table 11 summarizes the 
clinical features of the patients at evaluation. 
 
3.2. NEXT GENERATION SEQUENCING ANALYSIS 
 
The inherited forms of cardiomyopathies can be caused by mutations in at least many 
different genes. A literature review about sarcomeric and non-sarcomeric genes correlated to 
cardiomyopathies was carried out using public database such as ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/) 
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and GeneReviews® (https://www.ncbi.nlm.nih.gov/books/NBK1116/). We analyzed 63 
sarcomeric and non-sarcomeric genes in order to identify sarcomeric genes mutations in 
patients affected by HCM and to discover the role of not only sarcomeric loci, but also of 
many different genes in the onset of hypertrophic cardiomyopathy. 
Genomic DNA from peripheral blood was tested by next generation sequencing with two 
custom designs for the cardiomyopathy panel, based on AmpliSeq strategy (ThermoFisher, 
Carlsbad, CA, USA). The first panel was designed to analyze coding, intronic junctions and 
UTR sequences of 62 genes (Fig. 22). Those comprised 12 sarcomeric loci (ACTC1, 
MYBPC3, MYH6, MYH7, MYL2, MYL3, MYOM1, NEBL, TNNC1, TNNI3, TNNT2, TPM1), 9 
cytoskeletal (CRYAB, DES, DMD, DTNA, EMD, FXN, LAMA4, PDLIM3, SGCD), 9 Z-disk 
(ACTN2, ANKRD1, CSRP3, LDB3, MYOZ2, MYPN, NEXN, TCAP, VCL), 6 desmosomal 
(DSC2, DSG2, DSP, FHL2, JUP, PKP2), 5 intracellular Ca++ homeostasis (CALR3, CASQ2, 
JPH2, PLN, RYR2), 3 genes encoding for K+ and Na+ channels and interacting proteins 
(ABCC9, CAV3, SCN5A) and 18 other non-sarcomeric loci (BAG3, CTF1, EYA4, GATAD1, 
GLA, ILK, LAMP2, LMNA, MYLK2, PRKAG2, PTPN11, RAF1, RBM20, TAZ, TMEM43, 
TMPO, TTR, TXNRD2). 
In summary, the panel included 36 genes known to be associated with HCM and dilated 
cardiomyopathy (ACTC1, ACTN2, ANKRD1, BAG3, CALR3, CAV3, CRYAB, CSRP3, DES, 
EYA4, GATAD1, ILK, JPH2, LAMA4, LDB3, LMNA, MYBPC3, MYH6, MYH7, MYL2, MYL3, 
MYLK2, MYOZ2, MYPN, NEXN, PDLIM3, PLN, RBM20, SGCD, TCAP, TMPO, TNNC1, 
TNNI3, TNNT2, TPM1 and VCL), 7 genes related with arrhythmogenic right ventricular 
cardiomyopathy and left ventricular non-compaction (DSC2, DSG2, DSP, DTNA, JUP, PKP2 
and TMEM43), 7 genes associated to malformation syndromes and storage disorders (ABCC9, 
GLA, LAMP2, PTPN11, PRKAG2, RAF1 and TTR), 4 genes related to myopathies and 
neuromuscular disorders (DMD, EMD, FXN and TAZ), 3 genes implicated in arrhythmia 
syndromes/ion-channel disease (CASQ2, RYR2 and SCN5A) and other 5 cardiovascular 
candidate genes (CTF1, FHL2, MYOM1, NEBL and TXNRD2).The second panel was 
designed to analyze coding, intronic junctions and UTR sequences of TTN genes. Table 4 
summarizes the genes included in the study as well as their function, associated disorder(s), 
chromosomal position and sequencing details. The design allowed the targeted resequencing 
of 2890 amplicons (global size: 345,39 kb/patient) by Ion Torrent PGMTM instrument 
(ThermoFisher, Carlsbad, CA, USA). In order to validate the applied NGS protocol the entire 
coding sequences of MYH7, MYBPC3, TNNT2 and TNNI3 genes of 23/44 patients were at 
first analyzed by Sanger sequencing. 
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Figure 22. Schematic representation of of the 62 genes included in the first custom NGS panel 
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No Gene ID Description Cellular Function Disease symbol Chromosomal Location Target (bp) Amplicons Coverage (%) 
Missed 
(bp) 
Exonic 
missed (bp) 
1 ABCC9 
ATP-binding cassette, sub-family 
c  
ATP-binding cassette transporter, ATP-sensitive potassium channels CANTU’ SYNDROME;DCM10;ATFB12 
chr12:21,950,305-
22,089,648 
10.022 83 81,4 1.868 178 
2 ACTC1 Actin, alpha, cardiac muscle 1 Sarcomere, thin filament, muscle contraction ASD5;DCM1R;HCM11;LVNC4 
chr15:35,080,278-
35,087,947 
3.973 31 97,5 101 0 
3 ACTN2 Actinin, alpha 2 Actin-binding protein, localized to the Z-disc DCM1AA 
chr1:236,849,751-
236,927,578 
5.368 46 97,7 126 0 
4 ANKRD1 
Ankyrin repeat domain-containing 
protein 1 
Nuclear transcription factor that negatively regulates the expression of 
cardiac genes 
DCM 
chr10:92,671,838-
92,681,052 
2.334 22 96,4 84 0 
5 BAG3 Bcl2-associated athanogene 3 Anti-apoptotic activity DCM1HH;MFM6 
chr10:121,410,863-
121,437,349 
2.729 20 97,7 64 40 
6 CALR3 Calreticulin 3 
Ca(2+)-binding chaperones localized in the endoplasmic/sarcoplasmic 
reticulum 
HCM19 
chr19:16,589,849-
16,607,023 
1.652 15 96,9 52 8 
7 CASQ2 Calsequestrin 2 
Calcium ion reservoir within the sarcoplasmic reticulum of cardiac 
myocytes 
CPVT2 
chr1:116,242,607-
116,311,446 
3.140 28 98,2 55 35 
8 CAV3 Caveolin 3 Scaffolding protein within caveolar membranes 
RMD;MPDT;LQT9;CREATINE PHOSPHOKINASE  
ELEVATED SERUM;HCM1 
chr3:8,775,467-8,788,471 2.735 12 100 0 0 
9 CRYAB Crystallin, alpha b (basic) Cytoskeletal MFM;DCM1II;CTRCT16;MFM2 
chr11:111,779,331-
111,782,493 
811 7 100 0 0 
10 CSRP3 
Cysteine and glycine-rich protein 
3 (cardiac LIM protein) 
Positive regulator of myogenesis, role in the organization of cytosolic 
structures in cardiomyocytes 
HCM12;DCM1M 
chr11:19,203,559-
19,223,609 
1.651 16 100 0 0 
11 CTF1 Cardiotrophin 1  Secreted cytokine that induces cardiac myocyte hypertrophy - 
chr16:30,907,909-
30,914,901 
1.940 10 62,3 731 369 
12 DES Desmin Muscle-specific class III intermediate filament LGMD2R;DCM1I;MFM1;SCPNK 
chr2:220,283,080-
220,291,481 
2.608 26 100 0 0 
13 DMD Dystrophin 
Part of the dystrophin-glycoprotein complex , which bridges the inner 
cytoskeleton (F-actin) and the extra-cellular matrix; ligand for 
dystroglycan 
DCM3B;DMD;BMD chrX:31,137,326-33,357,746 19.739 188 98,5 302 
14 DSC2 Desmocollin 2 Component of intercellular desmosome junctions ARVC11 
chr18:28,645,923-
28,682,408 
5.925 52 86,9 777 222 
15 DSG2 Desmoglein 2 Component of intercellular desmosome junctions DCM1BB;ARVC10 
chr18:29,078,008-
29,128,834 
6.253 52 87,8 760 220 
16 DSP Desmoplakin Major high molecular weight protein of desmosomes 
ARVC8;PPKS2;EPIDERMOLYSIS BULLOSA, 
LETHAL ACANTHOLYTIC;DCWHK 
chr6:7,541,851-7,586,966 11.228 91 98,6 160 80 
17 DTNA Dystrobrevin, alpha  Component of the dystrophin-associated protein complex LVNC1 
chr18:32,073,235-
32,471,828 
16.922 98 93,7 1.074 
18 EMD Emerin 
Serine-rich nuclear membrane protein; membrane anchorage to 
cytoskeleton 
EDMD 
chrX:153,607,578-
153,609,903 
1.579 15 100 0 0 
19 EYA4 Eyes absent homolog 4 Tyrosine phosphatase that promotes efficient DNA repair DCM1J;DAD10 
chr6:133,562,476-
133,853,278 
6.634 62 98,5 99 7 
20 FHL2 Four and a half LIM domains 2  Component of intercellular desmosome junctions - 
chr2:105,977,264-
106,055,250 
2.800 21 97,4 74 
21 FXN Frataxin Cytoskeletal FRDA chr9:71,650,460-71,715,114 7.832 52 81,5 1.452 
22 GATAD1 
GATA zinc finger domain 
containing 1  
Regulates gene expression DCM2B chr7:92,076,746-92,088,762 4.155 24 68 1.330 
23 GLA Galactosidase, alpha  Lysosomal FABRY disease 
chrX:100,652,760-
100,663,021 
1.698 16 100 0 0 
24 ILK Integrin-linked kinase  
Receptor kinase regulating integrin-mediated signal transduction; 
important in the epithelial to mesenchymal transition 
DCM1A chr11:6,624,945-6,632,119 2.916 24 100 0 0 
25 JPH2 Junctophilin 2 
Component of junctional membrane complexes; necessary for proper 
intracellular Ca(2+) signaling in cardiac myocytes via its involvement in 
ryanodine receptor-mediated calcium ion release 
HCM17 
chr20:42,740,318-
42,816,238 
6.221 49 94,9 317 317 
26 JUP Junction plakoglobin 
Common junctional plaque protein in desmosomes and intermediate 
junctions 
ARVC12;NAXOS DISEASE 
chr17:39,910,840-
39,942,984 
5.140 37 100 0 0 
27 LAMA4 Laminin, alpha 4 Noncollagenous constituent of basement membranes DCM1JJ 
chr6:112,429,115-
112,575,848 
9.735 89 97,5 248 9 
28 LAMP2 
Lysosomal-associated membrane 
protein 2 
Lysosomal DANON 
chrX:119,559,984-
119,603,224 
12.307 71 90,5 1.169 0 
29 LDB3 LIM domain binding 3 Cytoskeletal assembly, targeting and clustering of membrane proteins DCM1C;LVNC3;MFM4 
chr10:88,428,187-
88,495,844 
7.364 59 95 365 0 
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30 LMNA Lamin A/C Components of the nuclear lamìna 
HEART-HAND SYNDROME, SLOVENIAN TYPE; 
MALOUF SYNDROME;MUSCULAR DYSTROPHY, 
CONGENITAL RESTRICTIVE 
DERMOPATHY,LETHAL;MADA;LGMD1B;FPLD2; 
HGPS;EDMD3;EDMD2;DCM1A 
chr1:156,084,442-
156,109,898 
3.958 34 95,6 173 0 
31 MYBPC3 Myosin binding protein c Myosin-associated protein DCM1MM;HCM4;LVNC10 
chr11:47,352,938-
47,374,273 
5.577 61 100 0 0 
32 MYH6 Myosin, heavy chain 6, alpha Alpha heavy chain subunit of cardiac myosin ASD3;DCM1EE;HCM14;SSS3 
chr14:23,851,180-
23,877,506 
7.501 73 98,1 142 131 
33 MYH7 Myosin, heavy chain 7, beta Heavy chain subunit of cardiac myosin 
DCM1S;HCM1;MPD1;LVNC5;MYOPATHY,MYOSIN 
STORAGE;SPMM 
chr14:23,881,928-
23,904,890 
7.630 77 97,1 225 225 
34 MYL2 
Myosin, light chain 2, regulatory, 
slow 
Regulatory light chain of myosin HCM10 
chr12:111,348,605-
111,358,424 
1.109 11 100 0 0 
35 MYL3 Myosin, light chain 3, alkali, slow Regulatory light chain of myosin HCM8 chr3:46,899,338-46,904,993 1.209 13 98,1 23 0 
36 MYLK2 Myosin light chain kinase 2 Myosin light chain kinase; calcium/calmodulin dependent enzyme HCM1 
chr20:30,407,159-
30,422,520 
3.313 35 99,7 11 0 
37 MYOM1 Myomesin 1 Major component of the myofibrillar M band - chr18:3,066,786-3,220,126 7.367 73 99,2 62 41 
38 MYOZ2 Myozenin 2 Involved in linking Z-line proteins HCM16 
chr4:120,056,920-
120,108,964 
2.837 23 93 198 0 
39 MYPN Myopalladin 
Tethers together nebulin (skeletal muscle) and nebulette (cardiac muscle) 
to alpha-actinin, at the Z lines 
DCM1KK;CMR4;HCM22 
chr10:69,865,855-
69,971,793 
7.648 61 87,7 937 671 
40 NEBL Nebulette  
Binds actin and interacts with thin filaments and Z-line associated 
proteins 
- 
chr10:21,068,884-
21,463,136 
17.194 102 97,3 456 262 
41 NEXN Nexilin Actin-binding protein DCM1CC;HCM20 chr1:78,354,181-78,409,598 3.909 38 97,9 82 42 
42 PDLIM3 PDZ and LIM domain 3 Involved in cytoskeletal assembly DM1 
chr4:186,421,796-
186,456,732 
3.400 28 96,5 118 98 
43 PKP2 Plakophilin 2 
Localizes to cell desmosomes and nuclei, regulates the signaling activity 
of beta-catenin, and participates in linking cadherins to intermediate 
filaments in the cytoskeleton 
ARVC9 
chr12:32,943,661-
33,049,800 
4.999 44 88,1 593 235 
44 PLN Phospholamban Inhibitor of cardiac muscle sarcoplasmic reticulum Ca(2+)-ATPase DCM1P;HCM18 
chr6:118,869,423-
118,881,607 
1.794 13 83,8 290 0 
45 PRKAG2 
Protein kinase, amp-activated, 
gamma 2 non-catalytic subunit 
Member of the AMPK gamma subunit family 
WPW;GLYCOGEN STORAGE DISEASE OF 
HEART,LETHAL CONGENITAL;HCM6 
chr7:151,253,182-
151,574,336 
4.773 41 87,2 610 360 
46 PTPN11 
Protein tyrosine phosphatase, non-
receptor type 11  
Regulates cell growth, differentiation, mitotic cycle, and oncogenic 
transformation 
JMML;METCDS;NS1;LEOPARD SYNDROME,1 
chr12:112,856,517-
112,947,737 
6.923 54 91,8 568 83 
47 RAF1 
V-RAF-1 murine leukemia viral 
oncogene homolog 1 
Regulates cell division, apoptosis, differentiation and migration NS5;LEOPARD,2 chr3:12,625,081-12,705,720 3.955 39 100 0 0 
48 RBM20 RNA binding motif protein 20 Regulates splicing DCM1DD 
chr10:112,404,136-
112,599,247 
7.793 63 96,7 254 10 
49 RYR2 Ryanodine receptor 2 Component of a calcium channel ARVC2;CPVT1 
chr1:237,205,683-
237,997,308 
20.565 219 95,8 855 306 
50 SCN5A 
Sodium channel, voltage-gated, 
type v, alpha subunit 
Sodium channel subunit 
SUDDEN INFANT DEATH 
SYNDROME;VENTRICULAR FIBRILLATION 
DURING MYOCARDIAL 
INFARCTION,SUSCEPTIBILITY 
TO;SSS1;LQT3;PFHB1A;BRGDA1;DCM1E;ATFB10 
chr3:38,589,534-38,691,184 10.353 87 96,5 365 0 
51 SGCD Sarcoglycan, delta Component of the sarcoglycan complex DCM1L;LGMD2F 
chr5:155,753,748-
156,194,818 
10.668 78 97,9 222 0 
52 TAZ Tafazzin Mitochondrial cardiolipin transacylase BTHS 
chrX:153,639,858-
153,650,083 
2.535 26 98,2 45 13 
53 TCAP Titin-cap 
Muscle assembly regulating factor. Mediates the antiparallel assembly of 
titin at the Z-disk 
DCM1N;LGMD2G 
chr17:37,821,580-
37,822,827 
1.043 9 100 0 0 
54 TMEM43 Transmembrane protein 43 Nuclear envelope protein ARVC5;EDMD7 chr3:14,166,421-14,185,200 3.822 35 98,4 61 19 
55 TMPO Thymopoietin Maintaining the structural organization of nuclear envelope DCM1T 
chr12:98,909,332-
98,944,177 
7.393 54 85,1 1.103 0 
56 TNNC1 Troponin c type 1 Central regulatory protein of striated muscle contraction DCM1Z;HCM13 chr3:52,485,088-52,488,077 936 10 100 0 0 
57 TNNI3 Troponin i type 3, cardiac Inhibitory subunit of troponin complex: blocking actin-myosin RCM1;HCM7;DCM2A;DCM1FF chr19:55,663,117- 1.121 14 100 0 0 
53 
interactions and thereby mediating striated muscle relaxation 55,669,120 
58 TNNT2 Troponin t type 2, cardiac Tropomyosin-binding subunit of the troponin complex HCM2;RCM3;DCM1D;LVNC6 
chr1:201,328,123-
201,346,825 
2.445 24 100 0 0 
59 TPM1 Tropomyosin 1 (alpha) Actin-binding protein DCM1Y;HCM3;LVNC9  
chr15:63,334,819-
63,364,133 
4.068 36 98,9 45 0 
60 TTR Transthyretin Carrier protein 
AMYLOIDOSIS,HEREDITARY,TRANSTHYRETIN-
RELATED;CTS1;DYSTRANSTHYRETINEMIC 
EUTHYROIDAL HYPERTHYROXINEMIA 
chr18:29,171,711-
29,179,006 
1.088 10 100 0 0 
61 TXNRD2 Thioredoxin reductase 2 Thioredoxin reductase - 
chr22:19,863,021-
19,929,379 
2.684 29 99,5 14 0 
62 VCL Vinculin F-actin binding HCM15;DCM1W 
chr10:75,757,853-
75,879,934 
6.366 60 96,1 246 33 
63 TTN Titin/connectin 
plays a key role in muscle assembly, force transmission at the Z line, and 
maintenance of resting tension in the I band region 
CMD1G, CMH9, LGMD2J, TIBIAL MUSCULAR 
DYSTROPHY, TARDIVE, MYOPATHY, EARLY-
ONSET, WITH FATAL CARDIOMYOPATHY 
Chr 2: 179.39 – 76.7 124134 877 98,4 
Table 4. Genes included in the 62 NGS panel. The acronym, function within the cell, associated disorder(s), chromosomal location and sequencing details are given for each 
gene. 
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3.2.1Next generation sequencing on Ion Torrent PGMTM System 
Ion Torrent PGMTM System is based on sequencing by-synthesis where pH changes caused 
by the release of protons when nucleotides are incorporated into the template strand. The 
ion’s charge is detectable by the ion sensor in the chip and as nucleotides are added, the 
voltage change is determined and data is displayed as a peak of voltage. These chemical 
signals are converted into digital information for ulterior analysis (Fig. 23). 
Figure 23. Ion semiconductor sequencing. As nucleotides are flowed across the chip, incorporation results in 
the release of a hydrogen ion that is detected by the chip. If identical nucleotides are incorporated 
(homopolymer), each H+ released will increase the signal detection (Images used thanks to Thermo Fisher) 
This platform permits higher speed, lower cost, and smaller instrument size. It was shown 
that Ion Torrent PGMTM has a stable quality along sequencing reads and a good performance 
on mismatch accuracies, rather then in detection of indels (Liu et al.; 2012) (Next Generation 
Sequencing. Translation to Clinical Diagnostics.Lee-Jun C. Wong editor, 2013). 
The fundamental strategy employed by this NGS platforms is to sequence millions of short-
DNA fragments in massively parallel arrays and then realign and map the short reads back to 
the reference genome. The basic steps used for this work include these following steps (Fig. 
24):  
1. Fragmentation of selected genomic DNA into fragments of a few hundred bp;
2. Library generation by ligating adapter sequences on both ends of genomic fragments;
3. Enrichment of targeted regions of interest by multiplexed PCR-based methods;
4. Massively parallel sequencing to generate strings of bases called reads that are then
aligned and assembled against the reference genome, and interpreted. 
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Figure 24. Ion Torrent PGM sequencing workflow (Images used thanks to Thermo Fisher) 
During the first step in the workflow we generated libraries of DNA fragments flanked by the 
Ion Torrent adapters: during this phase, different short indexing tags called barcodes are 
ligated to the amplified fragment of DNA from each sample to get proper differentiation 
between samples (Fig. 25). The library construction process is critical to perform the most 
genomic coverage and obtain a good quality sequencing data (Next Generation Sequencing. 
Translation to Clinical Diagnostics.Lee-Jun C. Wong editor, 2013). 
Figure 25. Library construction process for the Ion TorrentPGMTM. After PCR amplification, adapters and
specific barcodes are ligated to the target DNA fragments with each sample. 
Once the library has been constructed, clonal amplification of each amplicon by a process 
called emulsion PCR (emPCR) is performed on the Ion OneTouch™ 2 System (Fig. 26), by 
wich single-stranded DNA fragments are attached to the surface of beads callen Ion Sphere 
Particles (ISPs). The basic simple of emPCR is the dilution and compartmentalization of 
template molecules in water droplets in a water-in-oil emulsion. Ideally, each droplet 
contains a single template molecule and fuction as a micro-PCR reactor (Kanagal-Shamanna 
et al.; 2016) 
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Figure 26. Schematic representation of emPCR (Images used thanks to Thermo Fisher) 
After the amplification step, multiple clonal copies of the single DNA template will be 
obtained. Beads containing DNA are selected from those without DNA during enrichment 
step, which helps to maximize the sequencing yield. The enrichment template positive ISPs 
are loaded into a Ion chip by a short centrifugation step, and after that, the chip is placed on 
the PGM platform and the DNA is ready for the sequencing run (Kanagal-Shamanna et 
al.;2016). 
Ion Torrent has released Ion 314, Ion 316, and Ion 318 chips (Tab. 5). The chips are different 
in the number of wells resulting in higher production within the same sequencing time. Ion 
316 v2 chip that we used for these sequencing runsenables the production of greater than 
100-400Mb data in 2 h with a read length of 200 bp. The run time also varies from 3 to 7 
hours depending on the chip selected (Next Generation Sequencing Technologies in Medical 
Genetics, Valencia C.A., Pervaiz M.A., Husami A., Qian Y., Zhang K.C., 2013). 
Table 5.Commercial chips for Ion Torrent PGM (Images used thanks to Thermo Fisher) 
During the sequencing run, dNTPs are released in order and diffuse to each well. Once a 
nucleotide is incorporated into the growing strand, a hydrogen ion is released, leading to a pH 
change due to its positive charge. Changes in pH are converted into voltage alterations and 
the electrical signals will be processed and translated into sequence reads. The number of 
released ions is proportional to that of the incorporation events. When two identical 
nucleotides are incorporated, two hydrogen ions will be released and the reading of the digital 
signal will also double. But if the released nucleotide is not complementary to the template, 
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no hydrogen ion will be generated and the pH in solution will not change, indicating there is 
no incorporation event. Once data is generated on the Ion Torrent PGMTM, it is automatically 
transferred to the Torrent Serve and it run through signal processing and base calling 
alghoritms that produce a lot of DNA sequences associated with individual reads.
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3.3 ANALYSIS OF NGS DATA: VARIANT CALLING, ANNOTATION AND PRIORITIZATION 
 
The data analysis of the total number and type of DNA variants identified for each patient was 
carried out bythe software Torrent Suite 4.0.Subsequently, the bioinformatics workflow adopted to 
assess the biomedical impact of the DNA variants resulting from the experimental study was 
defined by these points: 
I. Alignment to reference genome (reference assembly GRCh37/hg19) 
II. Coverage analysis (Coverage analysis plugin) 
III. Variant Calling (Variant Caller plugin) 
IV. Annotation of identified variants 
Variant calls were annotated by wANNOVAR Web Server (wannovar2.usc.edu/). The nucleotide 
variants with a Minor Allele Frequency (MAF) ≤0.01 both in the 1000 Genome Project (global and 
European) and in the NHLBI-ESP 6500 exome project (global) were filtered and designed as “rare 
variants”.  
 
3.4 SANGER VALIDATION AND IN SILICO ANALYSIS OF NEXT GENERATION 
SEQUENCING VARIANTS 
 
Sanger sequencing was the goal standard for validating DNA sequencing results from NGS 
analysis: between the selected variants, only the exonic and ±10 bp intronic ones were prioritized 
and validated by Sanger sequencing. The confirmed DNA changes were subjected to different in 
silico predictions, twelve methods were employed for assessing the possible pathogenicity of the 
identified missense changes (Tab. 9). The effect of missense changes on the structure and function 
of a human protein was predicted by: (i) SIFT (Sorting Intolerant From Tolerant), (ii) PolyPhen-2 
(Polymorphism Phenotyping v2) HDIV, that identifies human damaging mutations by assuming 
differences between human proteins and their closely related mammalian homologs as non-
damaging; (iii) PolyPhen-2 HVAR, that identifies human disease-causing mutations by assuming 
common human nsSNPs as non-damaging; (iv) Provean (Protein Variation Effect Analyzer); (v) 
LRT (Likelihood Ratio Test) that identifies conserved amino acid positions and deleterious 
mutations using a comparative genomics data set of multiple vertebrate species; (vi) Mutation 
Taster; (vii) Mutation Assessor; (viii) FATHMM (Functional Analysis through Hidden Markov 
Models); (ix) RadialSVM (Radial Support Vector Machine); (x) LRT (Logistic Regression Test); 
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(xi) CADD v1.3 (Combined Annotation–Dependent Depletion), a method for objectively 
integrating many diverse annotations into a single measure (C score) for each variant; and (xii) 
molecular modeling (Bottillo et al.; 2016a) (Bottillo et al.; 2016b). 
3.5 MOLECULAR MODELING 
Protein modelswere built using the homology modeling approach implemented in modeler-9 
package on these specific missense variants: MYBPC3 c.T1664C:p.M555T, MYBPC3 
c.C1112A:p.P371Q, RYR2 c.A3380G:p.E1127G, RYR2 c.G145A:p.R485Q, FHL2 c.G109T:p.A37S,
MYOM1 c.G2132A:p.R711H, MYOM1 c.C2131T:p.R711C, DSG2 c.A208G:p.I70V, CALR3 
c.A1036G:p.I346V, ABCC9 c.G2200A:p.V734I, e ILK c.G1086C:p.Q362H. PSI-BLAST was used
to find suitable structural templates for each sequence to model and the sequences of each protein 
target to model and its structural template were then aligned by using the program CLUSTALW. 
The model displaying the lowest objective function (Burke et al.; 1999), which measures the extent 
of violation of constraints from the structural templates, was taken as the representative model. 
Superimposition and root-mean-square deviation (RMSD) calculation of C traces of the 10 models 
were performed to detect the most variable and therefore less reliable modeled regions. These 
invariably corresponded to loop elements. Procheck (Laskowski et al.; 1996) was used to monitor 
the stereochemical quality of the representative models, whereas ProsaII (Sippl et al.; 2014) was 
used to measure the overall protein quality in packing and solvent exposure. 
3.6  STATISTICAL ASSESSMENT OF GENOTYPE-PHENOTYPE CORRELATIONS 
All statistical analyses were performed using SPSS (statistical software package version 20.0). For 
each patient, the clinical data and molecular data (i.e. total number nsSNVs, number of any class of 
nsSNVs) were tabulated (Tab.10). 
Phenotype data were presented as continuous variables obtained from clinical data and instrumental 
measurements. Categorical variables were shown as the presence/absence or grade, of the clinical 
feature. Continuous variables were summarized using means and standard deviations, while 
categorical variables were summarized using frequencies and percentages. 
The molecular data were presented as number of DNA rare (frequency ≤ 0.01) nsSNVs variants 
(non-synonimus single nucleotide variants) identified in each functional class. The genes carrying 
rare variants were indeed grouped into sarcomeric, desmosomal, K+ and Na+ channels and 
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interacting proteins, loci for mRNA splicing and cellular enzymes, cytoskeletal, Z-disk and Ca2+ 
homeostasis. 
Statistical correlations for non-syndromic patients were evaluated between the presence of rare 
DNA variants (or the family history) and the prevalence of phenotypic traits with the following 
methods: (i) Chi-square test when referred to categorical variables; (ii) unpaired two-tailed 
Student's t-test when related to continuous variable. Due to the relatively low number of patients no 
adjustments was planned for multiple testing; the analysis is therefore exploratory and results to be 
considered as hypotheses-generating. 
 
3.7 ANALYSIS OF THE X CHROMOSOMES METHYLATION STATUS 
 
Case 27 was affected by Danon's disease and an assay for evaluating the methylation status (i.e., 
inactivation) of the X chromosomes (XCI) was also investigated on DNA both from blood 
leukocytes and cardiac muscle obtained from the LV, RV, and the septum of the patient's explanted 
heart. The same test was also performed on her father's DNA in order to establish the parental 
inheritance of each X chromosome.The XCI pattern was determined by evaluating the cytosine 
methylation of CpG dinucleotides within the polymorphic Cytosine, Adenine and Guanine (CAG) 
repeat in the first exon of the androgen receptor (AR) gene, located on chromosome X (Elstein et 
al.; 2012) DNA was digested by methylation-sensitive restriction enzymes (i.e., HpaII).  Digestion 
protocol was characterized by the preparation of two samples of 500 ng DNA: one of them 
containing 10U of the methylation-sensitive restriction enzyme HpaII and its specific digestion 
tampon, and the other one containing only the digestion tampon (Tab.6). 
 
 Digestion Mix A Digestion Mix B 
DNA (500ng) 500/[quantification] 500/[quantification] 
Buffer tango (10x) 2 μl 2 μl 
HpaII 1μl  ____ 
H2O to volume to volume 
Vf 20 μl 20 μl 
 
Table 6. Digestion Mix for the analysis of the X chromosomes methylation status 
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Both digestion mixes were incubated overnight at 37° C, after that the enzyme was inactivated at 
65° for 20 minutes. After digestion, DNA amplification can occur only in presence of methylated 
restriction sites (inactive allele). Both a digested and an undigested DNA samples were then 
amplified by two different primer pairs specific for the AR locus.  
The samples were than amplified with PCR, using two couples of oligonucleotide specific for the 
AR locus: 
Couple 1: 
XinF1        5’-GCTGTGAAGGTTGCTGTTCCTCAT-3’ marked with 5′ FAM 
XinR1         5’-TCCAGAATCTGTTCCAGAGCGTGC-3’ 
Couple 2: 
XinF2          5’-GTGCGCGAAGTGATCCAGAA-3’          marked with 5′ HEX 
XinR2          5’-CCAGGACCAGGTAGCCTGTG-3’ 
Each sample was amplified in the Applied Biosystems 9700 Fast Thermal Cycler (Applied 
Biosystems, Foster City, CA) and run in duplicate.   
PCR Reaction Mix (Vf = 25μl) 
 PCR BUFFER 10X: 2.5μl
 MgCl2 (25Mm): 1.5μl (conc. 1.5mM)
 dNTPs (2mM): 2.5μl (conc. 200μM)
 PRIMER F (10μM): 1μl
 PRIMER R (10μM): 1μl
 DMSO: 2,5 μl (10X)
 FastStart Taq DNA 5U/μl: 0,125μl
 Sterile distilled H2O: to volume
 DNA (from digestion): 4μl
PCR conditions: 
Initial denaturation: 95°c 4 min  
Cyclical denaturation: 95° 40 sec 
Annealing: 59°c 40 sec  
Cyclical extension: 72°c 40 sec  
Final extension: 72°c 30 min  
Cycles: 30 
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Polymerase Chain Reaction (PCR) products were separated an automated sequencer ABI3500xL 
(Thermo Fisher Scientific). GeneMapper 5 software (Thermo Fisher Scientific) was used for 
quantification and interpretation of raw data output. Peak heights of fluorescence intensity were 
used to calculate ratios. All samples were analyzed in triplicate, and the average values were used to 
assess the degree of X inactivation. The XCI skewing ratio was determined by comparing the ratio 
of allele peak heights in the digested sample (d1 and d2, for paternal and maternal allele, 
respectively) with the ratio in the undigested sample (u1 and u2), according to the following 
proportion: 
XCI percentage of the paternal allele=[(d1/u1)/{(d1/u1)+(d2/u2)}]×100, 
 
which ranges from 0% to 100% (Wardburton et al.; 2009).If this ratio is greater than or equal to 
80/20 the X inactivation is highly biased to allele 1; if greater than or equal to 75/25 the X 
inactivation is biased to allele 1; if about 50/50 the X inactivation is random. If a random X 
inactivation occurs, both alleles would be amplified; otherwise, if a preferential X inactivation 
occurs for the active chromosome’s allele, not methylated, it will be completely digested from the 
methylation-sensitive enzyme and only the other allele would be amplified. 
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4. RESULTS
4.1 GENOTYPING RESULTS 
Forty-four unrelated Caucasian/Italian patients (23 males and 21 females) were included in this 
study. Three patients displayed hypertrophic cardiomyopathy associated with a syndromic 
phenotype: case 10, 24 and 27 were respectively affected by a mild form of Fabry's disease, by 
Cantù's syndrome and by Danon's disease.  
High numbers, such as 3x106 reads (~700.000 reads) was obtained from the 62 genes NGS panel 
and 100x106 bp were aligned on the reference genome (reference assembly GRCh37/hg19). Each 
reads has a mean read length of 140 bp. Among the 44 patients the mean read depth of each 
analysed gene was 222X (Fig.27). 
Figure 27. Schematic representation of the read depth of 62 genes included in NGS panel (Bottillo et al.; 2016a, 
Supplementary Table 1)  
The total number of identified variants, before filtering for each patients is shown in Table 7.  
Subsequently the total number of the DNA variants was filtered and underwent Sanger sequencing. 
Among the 41 non-syndromic HCM cases, 33 (80%) were found to carry at least one rare non-
synonimus single nucleotide variants (nsSN). In total, 95 non-synonymous sequence changes, of 
which 87 different, were identified. These included 73 missense, 13 intronic, 3 frameshift, 4 
nonsense, one stop-loss and one in frame deletion. Among the 87 different nsSNVs, 21 were 
already reported in literature (Tab. 8). 
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Table 7. Numbers of DNA point mutations in 44 patients with hypertrophic cardiomyopathy (Bottillo et al.; 2016a, 
Supplementary Table 2)  
 
The proportion of non-synonimus single nucleotide variants (nsSNVs) identified for each analyzed 
gene is shown in Figure 28a. 
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Some patients showed the same eight nsSNVs: 
- CAV3c.C233T, p.T78M (patients 17,38); 
- CSRP3c.T10C, p.W4R (patients 8,25); 
- DSC2c.C1787T, p.A596V (patients 11,23); 
- MYBPC3 c.3192dupC, p.K1065fs (patients 31,46); 
- MYBPC3 c.T1664C, p.M555T    (patients 1,51); 
- PKP2c.G76A, p.D26N (patients 14,34); 
- PKP2 c.C2299A, p.R767S (patients 24,31); 
- RBM20c.G3373A, p.E1125K (patients 8, 25, 49). 
Figure 28a. Proportion of nsSNVs identified for each analyzed gene (Bottillo et al.; 2016a, Supplementary Table 1) 
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Table 8. Rare nsSNVs identified in 36/44 HCM patients. A comment inferred from review of literature, in silico predictions and evolution conservation analysis, is 
given for each DNA change in the last column. Based on those considerations and on the type of variant, comments with a gray background highlight DNA changes 
predicted to be possibly pathogenetic. Comments in bold stand for DNA variants that have been previously reported as phenotype modifying factors. Pt: patient; 1000G 
ALL: MAF in 1000 Genomes Project global; 1000G EUR: MAF in 1000 Genomes Project European; ESP6500si ALL: MAF in exome sequencing project global; Htz: 
heterozygosity; Hem: hemizygosity; Hmz: homozygosity; ClinVar SIG: signifiance in ClinVar database, including unknown (unk), non-pathogenic (nPath), probably-
non-pathogenic (PnPath), probably-pathogenic (PPath), pathogenic (Path); HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; CMD1M: 
cardiomyopathy, dilated, 1M; ARVC: arrhythmogenic right ventricular cardiomyopathy; IIE: intron identity element; VT: ventricular tachycardia; MHC: myosin heavy 
chain.Syndromic patients (Bottillo et al.; 2016a)
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The molecular analyses also identified 49 heterozygous synonymous variants (Tab. 9). 
Pt Gene Synonymous variant 
3 SCN5A c.T1764C, p.H588H
4 
SGCD c.G210A, p.R70R
TMEM43 c.C622T, p.L208L
7 SCN5A c.T1587C, p.I529I
8 MYH6 c.G5736A, p.A1912A
10 MYBPC3 c.A2781G, p.T927T
11 
DMD c.G1650A, p.Q550Q
RYR2 c.C3888T, p.N1296N
13 
VCL c.C1671T, p.D557D
VCL c.T1317C, p.S439S
LMNA c.G276A, p.L92L
14 LMNA c.G276A, p.L92L
17 MYPN c.A405C, p.A135A
19 
MYH7 c.C4134T, p.D1378D
MYOM1 c.A2658G, p.K886K
GATAD1 c.T456C, p.G152G
20 
TPM1 c.T519G, p.A173A
MYH6 c.C480T, p.N160N
21 TXNRD2 c.1308C>T, p.F436F
23 LAMA4 c.T924C, p.H308H
24 
VCL c.T1317C, p.S439S
LMNA c.G276A, p.L92L
27 
DSP c.G4383A, p.E1461E
MYOZ2 c.A237G, p.A79A
MYH7 c.C1410T, p.F470F
31 LAMA4 c.T924C, p.H308H
33 PRKAG2 c.C507T, p.T169T
34 DSG2 c.G2340T, p.A780A
35 
DSC2 c.A1350G, p.R450R
TMPO c.G1539A, p.L513L
MYH7 c.C1410T, p.F470F
37 DSC2 c.A348G, p.Q116Q
38 LAMA4 c.T924C, p.H308H
43 
LDB3 c.T546C, p.S182S
RYR2 c.C1863T, p.H621H
44 
EYA4 c.G714A, p.T238T
VCL c.T1317C, p.S439S
ABCC9 c.C2523T, p.A841A
45 
SCN5A c.G744A, p.K248K
MYH7 c.C1410T, p.F470F
46 MYH7 c.C1410T, p.F470F
25 LDB3 c.G273A, p.T91T
49 
RBM20 c.G1161A, p.A387A
RyR2 c.G13740A, p.T4580T
51 DSP c.G105A, p.G35G
52 
TMEM43 c.G333A, p.P111P
ANKRD1 c.T496C, p.L166L
55 
LDB3 c.G273A, p.T91T
DMD c.G1023T, p.V341V
Table 9. Numbers of heterozygous synonymous variants in 44 patients with hypertrophic cardiomyopathy (Bottillo et 
al.; 2016a, Supplementary Table 3) 
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No nsSNVs were identified between 25/62 genes: ACTC1, ANKRD1, CASQ2, CRYAB, CTF1, DES, 
EMD, EYA4, FXN, GATAD1, LDB3, MYL3, MYLK2, MYOZ2, NEXN, PLN, PRKAG2, PTPN11, 
SGCD, TAZ, TCAP, TMEM43, TNNC1, TNNI3 and TTR. 
About 33% of the changes mapped in sarcomeric loci, 19% in desmosomal loci, 15% in genes 
coding for K+ and Na+ channels and for channels-interacting proteins, 12% in genes coding for 
mRNA splicing and other cellular enzymes, 9% in cytoskeletal loci, 6% in genes related to 
intracellular Ca++ homeostasis, 5% in Z-disk loci and 5% in other non-sarcomeric loci (Fig. 28b). 
The 27% of the patients harbored two heterozygous DNA changes in different genes, 15% a single 
heterozygous change and 39% three or more variants (Fig. 28c). 
Twenty-four/41 of the cases harbored at least one sarcomeric nsSNV, and three patients carried 
only desmosomal changes. In total, 58% carried alterations in sarcomeric loci, 14% in desmosomal 
and 7% in other non-sarcomeric ones without any sarcomere change.  
 
 
 
Figure 28b. Proportion of nsSNVs identified for for each functional genic category. “Other” includes the loci coding 
for lysosomal, thioredoxin reductase, anti-apoptotic and membrane proteins (Bottillo et al.; 2016a) 
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Figure 28c. Number and zygosity of DNA changes identified over 37 HCM patients. Six cases were found to carry a 
single heterozygous nsSNV, 11 cases two heterozygous nsSNVs and 16 cases three or more nsSNVs. Four patients 
carried only synonymous changes, and four resulted negative to the NGS screening (Bottillo et al.; 2016a) 
Twenty-four/41 of the cases harbored at least one sarcomeric nsSNV, and three patients carried 
only desmosomal changes. In total, 58% carried alterations in sarcomeric loci, 14% in desmosomal 
and 7% in other non-sarcomeric ones without any sarcomere change. Figure 28d illustrates the 
fraction of mutated cases respect to the different genes' categories. 
Figure 28d. Proportion of mutated patients respect to the genes' category. Dashed slices (both white and gray) stand for 
cases harboring at least one sarcomeric non-synonymous variant. Light gray slices (both dashed and not dashed) 
represent patients not carrying any sarcomeric nsSNV, but at least one desmosomal one (Bottillo et al.; 2016a) 
In particular only one sarcomeric nsSNV was identified in patients 5, 36 and 46 and two sarcomric 
nsSNVs in patients 43 and 45.  
Seven patients (19, 23, 26, 31, 49, 10, 24) carried out at least, one sarcomeric nsSNVs associated 
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with one desmosomal variants and other variants. 
Case 44 showed two sarcomeric changes and two desmosomal nsSNVs. 
Instead 18 patients didn’t show any sarcomeric nsSNVs and among them, patients 14 and 37 
showed only desmosomal changes; patients 3, 27, 29 and 52 carried out only variants in other genes. 
The same 44 unrelated Caucasian/Italian patients affected by hypertrophic cardiomyopathy were 
analyzed by another NGS panel: the second panel was designed to analyze coding, intronic 
junctions and UTR sequences of TTN genes. Two thousand and five variants were identified in 
these patientsanalyzed by theTTN panel: 1588 exonic changes, 480 intronic changes, 20 UTR 
variants and 517 genetic variants in non-coding RNAs (ncRNAs) (Fig. 29).   
Figure 30shows the total number of DNA variantsdetected by TTN panel for each patients. 
 
 
Figure 29.  Variants identified in 44 HCM patients analyzed by TTNNGS panel 
 
 
 
Figura 30. Total number of TTN variants for each 44 HCM patients 
 
Subsequently, the total number of the titin changes was filtered with a MAF ≤ 0,05 and underwent 
to Sanger sequencing (Fig.31).  
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Figure 31. Total number of TTN variants for each 44 HCM patients after filtration (MAF ≤ 0,05) 
Among the 44 HCM cases: 52% were found to carry nsSNVs, 20% carried SNVs, 13% indels 
frameshift variants and 1% indels non-frameshift, 12% carried nonsense changes and 2% harbored 
non-frameshift variants (Fig. 32). 
Figure 32. Proportion of the 44 patients with TTN changes (MAF ≤ 0,05) respect to the variants' category 
4.2 IN SILICO PREDICTIONS 
Twelve methods were employed for assessing the possible pathogenicity of the identified missense 
changes (Tab.10). The variants with at least 6/12 deleterious predictions have been considered 
possibly pathogenetic, while a “no predicted deleterious effect” was accounted for those scored 
with two or less deleterious predictions. The in silico scores were completely concordant for 20 
variants (14 benign and 6 deleterious), but ambiguous for 19 changes which resulted in 3 to 5 
deleterious predictions among 12 ones. Nine among the 14 different intronic variants were 
1      2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19    20     21    22    23    24    25    26    27    29    31    32    33    34    35    36    37    38    43    44    45    46    49    51    52    55 
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predicted to alter a splicing site. Among the 85 different nsSNVs identifid in this study, 24 resulted 
in the alteration of an allele that is highly conserved across evolutionarily distant species (Tab.8). 
For those DNA changes, the four computational methods employed for the nucleotides' 
conservation analysis gave concordant scores (Tab.10). 
Inferring from the type of the variant, querying of frequency and mutational databases, as well as 
from the output of in silico predictions, all but three (patient 3, 37 and 52) mutated cases harbored 
at least one non-synonymous DNA change predicted to be pathogenetic, or already reported as 
disease-modifying factor (Tab. 8) 
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Table 10. Results of in silico prediction of the non-synonimus changes found in 41 HCM patients and in 3-HCM-
related cases by 6. Deleterious predictions are in bold (Bottillo et al.; 2016b) 
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Regarding the molecular modeling (in collaboration with Prof. Paiardini - Dept. of Biochemical 
Sciences “A. Rossi Fanelli”, Sapienza University of Rome, Rome, Italy), protein structures were 
experimentally determined by X-ray crystallography, or were inferred by homology modeling 
means (i.e., availability of a structural template with percentage of identity 4 20%). Protein models 
were built using the homology mod- eling approach implemented in modeler-9 package (Eswar et 
al.; 2007) (Bottillo et al.; 2016b).  PSI-BLAST was used to find suitable structural templates for 
each sequence to model (Friedberg et al.; 2000) (Bottillo et al.; 2016b). The sequences of each 
protein target to model and its structural template were then aligned by using the program 
CLUSTALW (Thompson et al.; 1994) (Bottillo et al.; 2016b) and manually manipulated to 
optimize the matching of several characteristics, including the observed and predicted secondary 
structural elements, the hydrophobic regions in the three-dimensional structures, the structurally and 
functionally conserved residues, and indel regions in the structures (Bottillo et al.; 2016b). Then, 
ten different models were built for each target protein and evaluated using several criteria. The 
model displaying the lowest objective function (Burke et al.; 1999) (Bottillo et al.; 2016b), which 
measures the extent of violation of constraints from the structural templates, was taken as the 
representative model. Superimposition and root-mean-square deviation (RMSD) calculation of C 
traces of the 10 models were performed to detect the most variable and therefore less reliable 
modeled regions. These invariably corresponded to loop elements. Procheckwas used to monitor the 
stereochemical quality of the representative models (Laskowski et al.; 1996) (Bottillo et al.; 2016b), 
whereas ProsaIIwas used to measure the overall protein quality in packing and solvent exposure 
(Sippl et al.; 1993) (Bottillo et al.; 2016b). Mutations on protein structures were carried out using 
the “Mutate model” script implemented in modeler-9 package (Eswar et al.; 2007) (Bottillo et al.; 
2016b).The script takes as input a given three-dimensional structure of a protein (experimentally 
determined or predicted), and mutates a single residue. The residue sidechain's position is then 
optimized by energy minimization and refined by molecular dynamics simulations. Prediction of 
protein stability upon mutation was carried out using the DUET server (Pires et al.; 2014) (Bottillo 
et al.; 2016b). Sequence identity between the modeled domain and its closest template ranged from 
23% (Laminin G-like domain of LAMA4), to nearly 95% (N-terminal globular head domain of 
VCL). However, in spite of the low value of sequence identity measured in some cases, all of the 
models resulted in a good overall quality (Prosa Z-score  -2.00), except for CALR3 and SCN5. 
Given the short length of the predicted PB035848 domain of CALR3 (residues 294-347) and its 
sequence identity with its template (61%), the measured Prosa Z-score (-1.93) nonetheless indicated 
a model of quality comparable to a Nuclear Magnetic Resonance (NMR) structure (Fig.33-34) 
(Sippl et al.; 1993) (Bottillo et al.; 2016b). 
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Figure 33. Structural comparison of wild-type and mutant forms for (a) FLH2 A37S; (b) LAMA4 E1646G; (c) MYH6 
R23H; (d) MYH7 A226T; (e) MYH7 R143Q; (f) MYOM1 R711H; (g) PKP2 R767S; (h) RYR2 E1127G; (i) RYR2 
R485Q. The mutation is indicated in white. The predicted structural effects of mutations are: (a, d) steric hindrance (red 
circles); (b) local misfolding of linker domain (orange); (c, e, f, g) loss of important inter-residues contacts; (h) loss of a 
π-anion interaction; (i) loss of a π-cation interaction (Bottillo et al.; 2016b) 
Figure 34. Effects of nsSNVs for: (a) the cadherin domain of DSC2. The mutant R199C in the cadherin domain of 
DSC2 is predicted to introduce a disulfide bond with the near Cys197 residue (C-Cdistance 6Âe), and possibly to 
result in local misfolding of the cadherin domain; (b) the melibiase domain of GLA. Mutant N215S of the melibiase 
domain of GLA results in the loss of a glycosylated site probably affecting the protein structure and/or function; (c) the 
FGF13 interaction domain of SCN5. Mutation I869F localizes on a solvent-exposed hydrophobic path of the domain of 
interaction with fibroblast growth factor 13 (FGF13). The I869F mutation could affect the recognition of the FGF13 
protein; (d) the Na-Channel of SCN5. The mutant D872N results in the loss of a negative charge that is approximately 
located at the Na-channel domain of SCN5, probably affecting cations conductance of the channel. The approximate 
position of the negatively charged Asp872 residue is shown in red, in each of the four protein subunits forming the 
channel (Bottillo et al.; 2016b) 
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4.3 GENOTYPE–PHENOTYPE CORRELATIONS 
Genotype phenotype correlation between nsSNVs identified in the 62 cardiovascular genes and the 
41 patients with non-syndromic hypertrophic cardiomyopathy was carried out on this study 
(Tab.11). It was observed an inverse correlation between the age at diagnosis and the total number 
of nsSNVs: the mean age at diagnosis was indeed 60 years in the group without variants and 43.8 
years in the group with variants (P = 0.01). The presence of nsSNVS in the genes involved in 
intracellular Ca++ homeostasis was significantly correlated to an earlier HCM onset: the mean age 
at diagnosis was in fact 35.8 years between the cases carrying those variants, versus 48.2 years in 
the cases without them (P = 0.03). The mean value of maximum wall thickness was lower both in 
the group carrying nsSNVs in genes for K+ and Na+ channels (P = 0.03), and in the group not 
harboring variants for Ca++ homeostasis (P = 0.05). Moreover it was observed a correlation 
between maximum wall thickness and the family history, as the mean of the MWT value of was 
lower in the sporadic group (18.055 mm) than in the familial group (22.3 mm) (P = 0.05). The 
occurrence of non-synonymous changes in cytoskeletal loci was correlated with the presence of 
non-sustained ventricular tachycardia: NSTV was indeed present in 40% of the patientscarrying 
cytoskeletal nsSNVs, versus 11% of patients not carrying them (P = 0.05). NSTV was also 
correlated with familial cases, respect to sporadic ones (P = 0.02). Cytoskeletal variants were 
correlated with a minor grade (grade 0–1) of diastolic dysfunction (P = 0.004) and, regarding New 
York Heart Association (NYHA) functional classification, sarcomeric variants were present in all 
grade I (no limitation of physical activity), in 56% of grade II (slight limitation of physical activity), 
and in 33% of grade III (marked limitation of physical activity) patients (P = 0.05). The prevalence 
of male sex was higher, respect to female in the group carrying at least one nsSNV compared with 
the HCM patients with no rare nsSNV (P = 0.01).Finally we identified a statistically significant 
correlation between the presence of an implantable cardioverter-defibrillator and familyhistory (P = 
0.03): the implantation of ICD resulted to be linked to a familial framework.
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Pt Sex 
Dgn 
Age 
Fam 
His 
HTX NYHA MWT LVM CMRI LVEF 
Familial 
SCD 
HOCM SAR Ablation NSTV Sync/Presync VO2 
Diast 
Dys 
Failure 
Thor 
pn 
ECG 
Hyp 
Cond Abn Hpt ICD PMK Myct CVG AMI/NSTEMI CAB Variants Sarc Des K+-Na+ Spl/E/N Cyt Z-disk 
Ca++ 
hmst 
Other 
1 M 36 F - 2 29 91 DI 53 0 + - - - - 75 2 - + - - - - - - n.e. - - 2 1 - - - - - 1 - 
2 F 63 F - 3 24 n.e. n.e. 45 n.e. + AF - - - 46 2 + + - - - - + + - - - - - - - - - - - - 
3 M 64 F - 2 18 90 - 65 0 - - - - - n.e. 2 - - + - + - - - n.e. - - 1 - - - 1 - - - - 
4 F 42 F - 2 18 90 MI 65 0 - - - + + 55 2 - + - - - + - - n.e. - - - - - - - - - - - 
5 M 63 S - 2 27 137 - 60 0 - - - - - n.e. 2 - + + - + - - - n.e. - - 1 1 - - - - - - - 
6 M 60 F - 2 20 105 - 65 0 + AF - - - 77 2 - + - LBBB + - - + + - + - - - - - - - - - 
7 F n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. - - - - - - - - - 
8 M n.e. S - 1 16 98 - 65 0 + PSVT - + - 48 2 - - + - - - - - - - - 5 1 - - 1 2 1 - - 
9 F 40 F - 2 17 75 - 65 1 - AF - - - 65 2 - - + - + - + - n.e. - - 3 2 - - - - - 1 - 
11 M 36 F # 3 22 133 MI 50 0 - AF - + - 41 3 + - - - - + - - - - - 4 - 2 1 - - - 1 - 
12 F 65 S - 2 16 n.e. n.e. 67 0 + - - - - n.e. 1 - - - - - - - - - - - - - - - - - - - - 
13 M 46 F - 2 24 105 MI 70 0 + AF - - - 87 2 - - + - - - - - n.e. - - - - - - - - - - - 
14 F 54 S - 2 18 n.e. n.e. 65 0 + - - - - 70 2 - + + - + - - - n.e. - - 1 - 1 - - - - - - 
15 M 36 S - 1 15 101 - 80 0 - - - - - 84 - - + + - + - - n.e. n.e. n.e. n.e. 3 1 - - 2 - - - - 
16 F 60 S - 2 19 n.e. n.e. 60 0 - - - + - n.e. 2 - - + - - - - - n.e. - - - - - - - - - - - 
17 F 50 S - 2 14 91 MI 52 0 - - - - - 78 3 + + + LBBB - - - - n.e. - - 4 2 - 1 1 - - - - 
18 M 36 S # 3 16 100 MI 57 1 - PSVT - - - 60 3 + + - - - - - - n.e. - - 2 - 2 - - - - - - 
19 M 36 S + 3 14 n.e. n.e. 50 0 - PSVT - - - 65 3 + - - LAFB - - - - n.e. - - 6 1 2 1 - 1 - - 1 
20 F 19 F - 2 28 112 MI 71 0 - PSVT + + - 87 - - - + - - n.e. n.e. n.e. n.e. n.e. n.e. 2 - 1 - - 1 - - - 
21 M 22 S - 2 30 148 DI 75 0 + - - - - 60 2 - - + RBBB - + - - n.e. - - 5 2 - 1 - - - 2 - 
22 M 46 s - 1 27 92 T 75 0 + - - - - 70 2 - - + - + - - - n.e. - - 2 1 - - - - - - 1 
23 M 18 F - 1 27 151 T 75 0 - - - + + 53 - - + + - - + - - n.e. - - 4 2 1 - - 1 - - - 
25 F n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. 4 1 - - 1 - 1 - 1 
26 F 59 F - 2 19 75 MI 65 1 - - - + - n.e. 1 - - - - - - - - - - - 5 1 1 2 - 1 - - - 
29 F 50 F + 3 13 n.e. n.e. 25 0 - - - - - 40 3 + - - - - + - - - - - 1 - - 1 - - - - - 
31 M 45 F - 2 26 n.e. n.e. 70 0 + PSVT + - - n.e. 2 - - + + - - - + n.e. - - 3 1 1 - - - - 1 - 
32 M 48 n.e. - 2 17 90 - 70 0 + - - - - 85 2 - - + - + - - - n.e. - - 3 - 1 1 1 - - - - 
33 M 55 S - 2 22 94 - 67 0 + - - - - 70 2 - - - - + - - - - - - 2 1 - - - 1 - - - 
34 M 60 S - 1 18 90 - 73 0 - PSVT - - - 60 1 - - + - + - - - n.e. - - 6 2 1 2 - - - - 1 
35 M 40 S - 2 16 87 MI 74 0 - PSVT - - + 60 2 - + + - - - - - n.e. n.e. n.e. 2 1 - 1 - - - - - 
36 F 28 S - 2 17 70 MI 65 0 + PSVT - - - 60 2 - - + - - - - - n.e. - - 1 1 - - - - - - - 
37 M 60 S - 2 22 95 MI 70 0 + - - - - 62 2 - - + RBBB+LAFB + - - - n.e. - - 2 - 2 - - - - - - 
38 F 55 F - 2 18 85 - 80 0 + - - + - 60 2 - - - - - - - - n.e. - - 2 1 - 1 - - - - - 
43 M 16 F + 3 25 200 DI 45 1 - - - + + 27 3 + - + RBBB+LAFB - + - - n.e. - n.e. 2 2 - - - - - - - 
44 M 20 F - 2 26 n.e. n.e. 70 0 + - - - - 52 2 - + + - - - - n.e. n.e. n.e. n.e. 4 2 2 - - - - - - 
45 M n.e. F - 2 30 112 DI 50 0 - - - + + 45 3 - + + - - + - n.e. n.e. n.e. n.e. 2 2 - - - - - - - 
46 M 60 F - 1 18 91 MI 68 0 - PSVT - - - 90 2 - - - RBBB+LAFB + - - - - + n.e. 1 1 - - - - - - - 
49 F n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. 4 1 1 - 2 - - - - 
51 F 58 S - 2 17 n.e. n.e. 60 0 + SA - - + 65 2 - - - - - n.e. + n.e. n.e. n.e. n.e. 2 1 - - - - 1 - - 
52 F 58 S - 2 1 87 MI 80 0 - - - - + 70 1 - - - - - - + - n.e. n.e. n.e. 4 - - 1 - 2 1 - - 
55 F 70 n.e. n.e. n.e. 17 81 - 80 n.e. - n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. n.e. - - - - - - - - - 
Syndromic HCM 
10-Fabry F 60 S - 2 14 104 - 77 0 - - - - - 60 2 - - + - - - - - n.e. - - 4 1 1 - - - - - 2 
24-Cantù F 7 S - n.e. n.e. n.e. n.e. n.e. 0 - - - - n.e. - - - + - - - - - - - - - 5 1 2 1 - - - 1 - 
27-Danon F 14 F + 3 32 220 MI 55 0 - TPSV + - + 65 3 + - + LBBB - + - - - - - 2 - - - 1 - - - 1 
Table 11.  Clinical and molecular features of the 44 HCM patients. Patients 2, 4, 6, 7, 12, 13, 16 and 55 (highlighted in grey) did not harbor any low-frequency nsSNVs in the analyzed genes. Pt: patient; Dgn Age: age at diagnosis (years); n.e.: not evaluated; +: present; 
-: absent; Fam His: Family History (F: Familial; S: Sporadic); HTX: Heart Transplantation; #: dead before HTX; NYHA: New York Heart Association functional class; MWT: Maximal Wall Thickness (mm); LVM: Left Ventricular Mass (at CMRI) (mg/m2); CMRI: 
cardiac magnetic resonance areas of contrast (DI: diffused intramyocardial; MI: mild intramyocardial; T: transmural); LVEF: Left Ventricular Ejection Fraction (%); SCD: Sudden Cardiac Death (0: no relatives with SCD; 1: one or more relatives with SCD); HOCM: 
Obstructive Cardiomyopathy (outflow obstruction); SAR: Supraventricular Arrhythmias (PSVT: Paroxysmal Supraventricular Tachycardia; AF: Atrial Fibrillation; SA: Sinus Arrest); NSTV: Non-Sustained Ventricular Tachycardia; Sync/Presync: 
Syncope/Presyncope; VO2: maximal oxygen uptake (%); Diast Dys: Diastolic Dysfunction (grade); Thor pn: thoracic pains; ECG Hyp: ElectroCardioGram Hypertrophy criteria; Cond Abn: Conduction abnormalities (RBBB: Right Bundle Branch Block; LBBB: Left 
Bundle Branch Block; LAFB: Left Anterior Fascicular Block); Hpt: Hypertension; ICD: Intracardiac Defibrillator; PMK: Pacemaker; Myct: Myectomy; CVG: Coronary-Ventriculography; AMI/NSTEMI: Acute Myocardial Infarction Non-ST elevation Myocardial 
Infarction; CAB: Coronary Bypass; Variants: totalnumber of nsSNVs; Sarc: number of sarcomeric nsSNVs; Des: number desmosomal nsSNVs; K+-Na+: number of nsSNVs in genes for K+ and Na+ channels and interacting proteins; Spl/E/N: number of nsSNVs in 
mRNA splicing, cellular enzymes and nuclear genes; Cyt: number of cytoskeletal nsSNVs variants; Z-disk: number of Z-disk nsSNVs; Ca++ hmst: number of intracellular calcium homeostasis nsSNVs (Bottillo et al.; 2016a)
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4.4 PATIENTS WITH HCM ASSOCIATED WITH A SYNDROMIC PHENOTYPE 
Among the syndromic patients, case 10 was found to carry the p.N215S mutation in the GLA gene, 
previously associated with a mild form of Fabry disease (Davies et al.; 1993; Eng et al.; 1993), case 
24 harbored the ABCC9 p.R1154W mutation causing Cantù's syndrome (Harakalova et al.; 2012; 
van Bon et al.; 2012) and case 27 carried the novel LAMP2 p.F151fs mutation (Bottillo et al.; 
2016c). In addition, they were found to carry other rare nsSNVs (Tab.9). 
4.4.1 Patient 10 
Case 10 was a 65 years old woman affected by a mild form of Fabry’s disease. Genetic testing was 
performed by next generation cardio panel including 62 genes and the patient was found to carry 
the GLA c.A644G,p.N215S mutation. This mutation was already characterized like pathogenetic 
and it causes Fabry disease (Davies et al.; 1993) (Eng et al.; 1993). 
In order to determine an association between this mutation and the specific cardiac phenotype of 
this patient, we made an exhaustive literature review (http://fabry-database.org/),figure 35 shows 
the general distribution of the known GLA mutation correlated to the pathogenesis of Fabry’s 
disease (Fig.35). Over 500 pathologic GLA allelic variants have been identified, including missense 
and nonsense mutations, large and small gene rearrangements, and splicing defects. Most mutations 
are family-specific, occurring only in single pedigrees. However, mutations at CpG dinucleotides 
have been identified in unrelated families of different ethnic or geographic backgrounds. Haplotype 
analysis of mutant alleles that occur in two or more families revealed that individuals with rare 
alleles are most likely related, whereas individuals with mutations involving CpG dinucleotide “hot 
spots” are not. Very few de novo mutations have been detected (Ashton-Prolla et al.; 2000) 
(Oliveira de Alencar et al.; 2014) 
Figure 35. General distribution of GLA mutation correlated to Fabry’s disease. Others: more mutations in the same 
patients 
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4.4.2 Patient 24 
Case 24 was a 7 years old girl affected by Cantù’s syndrome. Genetic testing was performed by 
next generation sequencing and the patient was found to carry the ABCC9c.C3460T,p.R1154W 
mutation. This mutation was already descripted in previous studies (Harakalova et al.; 2012) (van 
Bon et al.; 2012). A literature review about ABCC9 mutations was carried out using public database 
such as ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and Pubmed (https://
www.ncbi.nlm.nih.gov/pubmed/). In total 28 ABCC9 pathogenetic mutations have been already 
reported (Fig.36). Among 16 different pathogenetic mutations, 13 are correlated to Cantu’s 
syndrome (Grange et al.; 2006) (Scurr et al.; 2011) (Harakalova et al.; 2012), 2 refer to dilatative 
cardiomyopathy  (Bienengraeber et al.; 2004) and 1 is correlated to the familial atrial fibrillation-12 
(ATFB12, OMIM 614050) (Olson et al.; 2007). Furthermore, other 12 mutations in the ABCC9 
gene have been prevoiously reported as“probably pathogenetic” or “variants with uncertain 
significance”. Notably, most of the ABCC9 mutations resided within exon 27 of ABCC9. 
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Figure 36. Schematic structure of ABCC9 gene and known mutations associated to HCM and Cantù’s syndrome White 
exons: NM_005691.3. Exons are in scale; introns are not in scale. Grey exons: NM_020297.3. To date, the discovered 
mutations map on the entire sequence. The mutation c.C3460T, p.R1154W mapped on exon 27 (in grey) 
4.4.3 Patient 27 
The patient, a 23-year-old female, was the only child born to unrelated Italian parents with a family 
history of cardiac disease (Fig.37). Her living father had developed chronic ischemic heart disease 
following a myocardial infarction at 52 years of age, while her mother began experiencing 
symptoms of progressive heart failure during the fourth decade of life, with the first hospital 
admission at age 39 with an ejection fraction (EF) lower than 30%. The diagnosis of idiopathic 
ABCC9 mutations correlated to 
primary hypertrophic 
cardiomyopathy 
ABCC9 mutations associated to 
Cantù's syndrome
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dilated cardiomyopathy was made in this woman who died 5 years later due to a cerebral 
hemorrhage complicating the implant of a ventricular assist device. Since childhood, the patient had 
manifested mild intellectual impairment. At the age of 20, she was referred to the cardiomyopathy 
unit, division of cardiology and cardiac arrhythmias, of our institution for supraventricular 
tachyarrhythmias. 
Figure 37. Familial pedigree of patient 27. The mother was affected by diatative cardiomyopathy. The father had a 
myocardial infarction at 52 years of age and the mother died at 54 years of age for a cerebral hemorrage complication 
Electrocardiogram exhibited a normal sinus rhythm with a preexcitation pattern (Fig.38A). 
Echocardiography revealed severe cardiomyopathy with symmetric hypertrophy, small ventricular 
cavity, and mild EF reduction (55%) (Fig.38B). The ventricular septum thickness was quite high 
(32 mm) as well as the posterior wall (28 mm). She underwent cardiac radiofrequency ablation of 
the accessory pathway. During follow-up, she complained of dyspnea and general weakness. A 
cardiac magnetic resonance (CMR) confimed the hypertrophic phenotype, showing a decrease in 
the EF (45%). Holter ECG revealed nonsustained ventricular tachycardia, requiring an implantable 
cardioverter defibrillator. Despite medical therapy, left ventricle function progressively decreased. 
At the age of 22, echocardiography showed a hypokinetic and dilated LV with an EF of 30%. 
Notably, LV hypertrophy was reduced compared to previous evaluations (ventricular septal 
thickness of 18 mm). 
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Figure 38. Echocardiographic and electrocardiographic features of the patient. (A) Echocardiogram showing marked 
left ventricular hypertrophy involving interventricular septum and lateral wall with increased echogenicity of the 
myocardium. (B) Rest 12-lead electrocardiography showing sinus rhythm with large delta waves due to overt 
ventricular preexcitation associated with markedly abnormal ventricular repolarization (Bottillo et al.; 2016c) 
 
One year later, the patient complained of profound muscular weakness. Serum CK levels were 
within the normal range. An echocardiogram confirmed a low EF (30%). Due to the severe 
muscular weakness, a deltoid muscle biopsy was performed, which showed normal morphologic 
features of myocytes (Fig.39A-B). However, increased phosphatase reactivity was observed in 
some muscle fibers. This finding, in light of the association of cardiomyopathy, myopathy, and mild 
mental retardation, suggested the diagnosis of Danon disease (DD). Immunofluorescence for 
LAMP2 protein was negative in about 10% of fibers, as compared to normal control muscle 
(Fig.39C-D), prompting a genetic evaluation to confim the suspicion. 
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Figure 39. Histopathology of the left deltoid muscle. (A) Hematoxylin and eosin stain; (B) Gomori's trichome stain; (C) 
Immunohistochemistry of LAMP2 protein in the patient's muscle sample. LAMP2 negative fibers are marked with 
asterisk. (D) Immunohistochemistry of LAMP2 protein in an aged-matched control. Bar corresponds to 20 m (Bottillo 
et al.; 2016c) 
4.4.3.1 Molecular genetic analysis and analysis of genotype-phenotype 
correlations 
The patient was found to carry two novel heterozygous nonsynonymous rare variants: a truncating 
mutation in LAMP2 (chrX:g.119582928delA, NM_013995:c.453delT, p.F151Lfs*32) (Fig. 40A 
and B) and an intronic alteration in LMNA (chr1: g.156108272TC, NM_001257374.1:c.1363-
7TC). 
The identified LAMP2 mutation allowed the definitive diagnosis of DD, while in silico studies did 
not disclose any functional role for the LMNA alteration. The LAMP2 c.453delT alteration was not 
found in blood leukocytes from her father. Thus, based on the clinical history of her deceased 
mother, a maternal inheritance was suspected.  
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Fig. 40. Molecular studies of patient 27 (A) DNA sequence chromatogram of the LAMP2 c.453delT mutation found in 
the patient. (B) Schematic structure of LAMP2 gene and known mutations associated to Danon disease. Exons are in 
scale; introns are not in scale. Exons belonging to isoform LAMP2B (NM_013995) are shown by grey rectangles. 
Exons 9A and 9C belonging, respectively, to isoforms LAMP2A (NM_002294.2) and LAMP2C (NM_001122606) are 
represented by white rectangles. The protein's functional domains are shown as colored boxes on the right of the exons. 
The nomenclature of each genomic change is given according to NM_013995, and the mutation found in the present 
patient is shown with a grey background. Truncating mutations (i.e., nonsense and frameshift) are shown on the right, 
while splicing, nonsynonymous, and synonymous alterations are shown on the left. The c.864GNA, p.Val288Val and 
the c.928GNA,p. Val310Ile were previously proven to cause the skipping of, respectively, exon 6 and exon 7. E: exon; 
TM: transmembrane region; CT: cytoplasmic tail (Bottillo et al.; 2016c) 
 
 
Indeed, figure 40B shows exon/intron structure and the alignment of all the known point mutations 
mapping in LAMP2. In total, 68 LAMP2 mutations have been reported in the literature (Danon et 
al.; 1981) (Nishino et al.; 2000) (Sugie et al.; 2002) (Balmer et al.; 2005) (Fanin et al.; 2006) 
(Spinazzi et al.; 2008) (Kim et al.; 2010) (Boucek et al.; 2011) (Dara et al.; 2011) (Cheng et al.; 
2012) (Eistein et al.; 2012) (Hedberg et al.; 2015) (Bottillo et al.; 2016a) (Bottillo et al.; 2016b) 
(Bottillo et al.; 2016c) and 16 additional sequence alterations have been annotated as “pathogenic” 
or “likely pathogenic” in the ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/). The 
mutations distribute along the entire gene sequence without evidence of hotspot nucleotides. The 
majority of sequence alterations map from exon 1 to exon 8, affecting all three LAMP2 isoforms. 
However, most of the splice site alterations map in intron 6 (Nishino et al.; 2000) (Bui et al.; 2008) 
(Cottinet et al.; 2011) (Hedberg et al.; 2015), and none of theme maps in introns 3 or 4. 
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Based on a review of published genetic and clinical data, we statistically tested some genotype–
phenotype correlations using chi-square test and two-tailed Student's t test to compare, respectively, 
categorical and continuous variables. The type and position of the mutations were used to 
categorize the genotype, while the following categories were used as a measure of phenotype 
severity: age of symptoms' onset, age of death, levels of serum CK, heart transplantation, WPW, 
cardiomyopathy, skeletal muscular weakness, pacemaker (PMK), ICD, and intellectual disability. 
We found a statistically significant correlation between mutations located in LAMP2 exons 1 to 8 
and a severe phenotype. Patients harboring alterations mapping in exons 1 to 8 showed indeed a 
higher frequency of WPW syndrome (P=0.04) and cardiomyopathy (P=0.0001), compared to 
patients mutated in exon 9B. Mutations in exons 1 to 8 actually alter all the three LAMP2 isoforms, 
while alterations of exon 9B are restricted to LAMP2B transcript. We then investigated the 
correlations between the type of mutation (i.e., truncating, missense, or splicing) and the clinical 
outcome. The implantation of PMK was correlated with the type of mutation, with PMK implanted 
in 6%, 12%, and 26% of patients with truncating, missense, or splicing mutations, respectively 
(P=0.05). In addition, we found that missense alterations correlated with a lower incidence of 
cardiomyopathy (Pb.0001). Finally, as previously described, we confirmed that truncating 
mutations show the earliest age of symptoms' onset (18±11 years). DD cases carrying splicing 
mutations tended to have onset later in life (20±13 years), while missense mutations showed the 
latest age of onset compared with all other mutations (32±23 years) (P = 0.04). 
4.4.3.2 Morphological and immunohistochemical analysis of explanted heart 
One year later, at the age of 23, the patient experienced severe heart failure and underwent 
orthotopic cardiac transplantation. Immediately after explant, the heart was weighed and 
photographed. Myocardial samples were obtained from multiple sites in both ventricles and were 
either processed for routine histology or snap frozen in liquid nitrogen-chilled isopentane for 
histochemical, biochemical, and molecular studies (in collaboration with Prof.ssa d’Amati, Dept. of 
Radiology, Oncology and Pathology, Section of Pathology, Policlinico Umberto I, Sapienza 
University of Rome, Rome, Italy). On gross examination, the explanted heart showed severe 
asymmetric left ventricular hypertrophy, mainly involving the septum (septal/free wall thickness 
ratio of 1.7). Multiple small foci of myocardial scarring were present, extensively involving the 
subepicardial and midventricular layers of the anterior, lateral, and posterior aspects of the LV free 
wall. Conversely, the ventricular septum involvement was limited to the anterior portion and 
consisted of sparse foci of scarring, within the subendocardium (Fig.41A).  
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Cardiac valves and coronary tree were unremarkable. 
At histology, cardiomyocytes were hypertrophic and showed sarcoplasmic vacuoles filled with 
Periodic Acid–Schiff (PAS)-positive granules (Fig.41B-C). Multiple foci of myofiber disarray with 
increased interstitial collagen were present both in the anterior wall and the septum (Fig.40D). The 
areas of replacement fibrosis in the LV free wall and septum showed a close spatial relationship 
with remodeling of intramural coronary arterioles, consisting of medial wall thickening due to 
smooth muscle cell hypertrophy and increased collagen deposition, with variable degrees of intimal 
thickening and perivascular fibrosis (Fig.41E-F) leading to severe lumen narrowing. 
Analysis of LAMP2 expression by immunohistochemistry, performed both on the LV and Right 
Ventricle (RV) free walls and on the septum, revealed a mosaic pattern consisting of discrete 
clusters of either stained or unstained cardiac myocytes (Fig.42A) Cells lacking LAMP2 were 
particularly frequent in the septum, accounting for about 60% of cardiac myocytes. At electron 
microscopy (EM) analysis cardiomyocytes showed disorganized myofibrils and autophagic vacu- 
oles containing myeloid bodies, electrondense granular material, and cytoplasmic debris. These 
vacuoles were surrounded by a single membrane. In addition, accumulation of free and vacuole 
bound glycogen was observed (Fig.42C-F). 
 
 
Figure 41. Macroscopic and histologic features of explanted heart. (A) Short-axis section of the heart showing 
biventricular, asymmetrical hypertrophy, mainly involving the septum (septum thickness = 23 mm; free wall LV 
thickness = 13 mm), with mild chamber dilation. LV free wall shows multiple foci of subepicardial and midventricular 
scarring. (B) Cardiac myocytes with prominent sarcoplasmic vacuoles (hematoxylin and eosin, original magnification 
x4). (C) The vacuoles contain PAS-positive granules (PAS, original magnification x20). (D) Myocardial disarray in the 
septum (hematoxylin and eosin, original magnification x10). (E) Remodeling and lumen narrowing of intramyocardial 
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arterioles associated with foci of scarring (Masson trichrome stain, original magnification x10). (F) Higher 
magnification of a remodeled vessel showing medial wall smooth muscle hyperplasia. (Masson trichrome stain, original 
magnification x40) (Bottillo et al.; 2016c) 
Figure 42. LAMP2 protein expression in cardiac myocytes. (A) Immunohistochemistry on the patient's heart shows 
discrete clusters of either stained (red) or unstained cardiac myocytes. Note a cluster of stained cardiac myocytes 
bordered by arrows. (B) Normal pattern of LAMP2 staining in a control heart (original magnification x20). (C-F) EM 
analysis of myocardium. (C-D) The photographs show myofibrils and intercalated discs disorganization. Autophagic 
vacuoles (arrowheads) and glycogen (arrows) are accumulated in cardiac myocytes. ID: intercalated disc, m: 
mitochondria. Original magnification: x5900 and x8900, respectively. (E) Higher magnification of autophagic vacuoles 
in a cardiac myocyte (arrowheads). Original magnification: x21,000. (F) Higher magnification of vacuoles containing 
glycogen (arrows). Original magnification x29,000 (Bottillo et al.; 2016c) 
4.4.3.3 Analysis of the X chromosomes methylation status 
Considering the severity of the disease manifestations and progression, an assay for evaluating the 
methylation status (i.e., inactivation) of the X chromosomes (XCI) was performed on DNA both 
from blood leukocytes and cardiac muscle obtained from the LV, RV, and the septum of the 
patient's explanted heart. The same test was also performed on her father's DNA in order to 
establish the parental inheritance of each X chromosome. The XCI pattern was determined by 
evaluating the cytosine methylation of CpG dinucleotides within the polymorphic Cytosine, 
Adenine and Guanine (CAG) repeat in the first exon of the androgen receptor (AR) gene, located on 
chromosome X (Warburton et al.; 2005) (Elstein et al.; 2012) (Bottillo et al.; 2016c). 
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The inactivation rate of the X chromosome maternally inherited (assumed to carry the c.453delT 
LAMP2 mutation) was 62% in blood leukocytes of our patient. The random X-chromosome 
inactivation found in the cardiac sections and leukocytes of patient 27 excluded the possibility that 
selective involvement of DNA both from blood leukocytes and cardiac muscle obtained from the 
LV, RV and the septum is due to skewed X-chromosome inactivation.   
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5. DISCUSSION
This study reports a next generation analysis of the prevalence of sarcomeric and non-sarcomeric 
gene variants in 41 patients affected by primary hypertrophic cardiomyopathy, and in 3 cases 
affected by syndromic HCM. This work was aimed the discovery of disease causing genetic 
variation for an appropriate genetic counseling, as well as for the enlargement of the hypertrophic 
cardiomyopathy mutational spectrum thorough a broad genetic test.  
The employed high throughput sequencing technology enabled the generation of large amounts of 
sequence data, and determined the need of an accurate assessment of the identified genetic varia- 
tions. The experimental characterization of all the observed DNA changes would have support the 
functional and/or regulatory impact of the various mutations, but it requires a long experimental 
time that was impractical in our clinical setting. Likewise, co-segregation analysis of the DNA 
changes within families would have been appropriate, but it is uninformative in small pedigrees and 
it is hindered by HCM incomplete penetrance and variable expressivity. 
A high number of bioinformatics solutions for the annotation, scoring and classification of variants 
are currently available to address the challenge of predicting the functional consequences of a 
mutation. Our results show the relevance of incorporating integrated computational workflows to 
predict the biomedical impact of the various DNA variants resulting from a NGS approach, and to 
identify functionally significant or clinically actionable variants. 
After the initial quality assessment of the sequencing reads, their alignment with the reference 
genome, and the subsequent variant calling, the resulting DNA changes were annotated for 
facilitating the filtering and prioritization steps. Some online free sequence databases such as 1000 
Genome Project, NHLBI-ESP 6500 exome projects and dbSNP138, were helpful in the annotation 
process. Since all the patients included in this study were Italian, we checked the frequency of each 
variant both in 1000 Genomes Project Global and Exome Sequencing Project Global, but also in 
1000 Genomes Project European. Based on those datasets we considered only variants with an 
allele frequency ≤ 0.01. Sanger sequencing was employed to rule out false positive calls from all 
the filtered and prioritized DNA changes. These analyses generated a subset of variants presenting 
several data interpretation challenges, but also some interesting genotype–phenotype cues. For 
further delineating the likelihood to be disease-relevant nsSNVs, we hence established a 
bioinformatics framework for the assessment of each variant functional role, based on previously 
reported data and in silico predictions. We evaluated the performance of several different 
independently published methods that aim to predict the functional consequences of alleles that 
result in amino acid substitutions. Moreover, the impact of a sequence variant with respect to the 
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evolutionary conservation was derived from genomic evolutionary rate profiling (GERP) score, 
phylogenetic P-value (PhyloP) score and PhastCons score. Those predictions aimed to hypothesize 
the probable impact of a particular genetic variant on function or regulation and suggested that most 
of the identified nsSNVs have the potential of being functionally pathogenetic. 
Several free online tools (i.e. SIFT, Polyphen 2_HDIV, Polyphen2_HVAR, Provean, LRT, 
Mutation Taster, Mutation Assessor, FATHMM, RadialSVM, LR, CADD v1.3) were employed to 
assess sequence- and structure-based features (Bottillo et al.; 2016b). Provean gave back a 
prediction score for every input variant. Between the other tools, LRT failed more frequently to 
give a result (16 not predicted variants out of 85 different ones). Regarding our set of DNA changes, 
Mutation Taster and Mutation Assessor were the methods resulting respectively in the greater and 
in the fewer number of deleterious predictions. We therefore observed that combining multiple 
prediction tools provides a more even balance between sensitivity and specificity than most of the 
individual methods. 
Besides the score-based predictions, performing molecular modeling gave us the opportunity of 
visually and directly testing tertiary or quaternary structure. The location of a coding SNV with 
respect to the surface-interior or interface of the protein structure-could indeed influence disease 
manifestation. 
Our NGS approach of 62 sarcomeric and non-sarcomeric genes identified likely pathogenic 
sarcomeric variants in 58% non-syndromic patients, consistent with previous studies that have used 
both conventional genetic sequencing techniques (Marian et al.; 2001; (Arad et al.; 2002b); 
(Hershberger et al.; 2013), and a NGS approach in larger cohorts. In particular, in 2013 Lopes and 
coauthors analyzed 223 unrelated cases for 41 sarcomeric and non-sarcomeric cardiovascular genes 
and found that 121 patients (54%) carried alterations in 9 sarcomeric genes (including ACTC1, 
MYPBC3, MYH6, MYH7, MYL2, MYL3, TNNI3, TNNT2 and TPM1) (Lopes et al.; 2013). In our 
study we found alterations in two additional sarcomeric loci (i.e. MYOM1 and NEBL) not analyzed 
by Lopes and colleagues, maybe explaining our slight increased rate of cases with sarcomere gene 
mutations. 
Inclusion of not only sarcomeric loci, but also of many different genes implicated in 
cardiomyopathies, resulted in the identification of several rare (frequency ≤ 0.01) DNA changes. 
We found that 82% of the patients harbored at least one rare nsSNV. Our results confirm the well-
established role of MYBPC3 a major gene in the HCM pathogenesis (Millat et al.; 2010); (Lopes et 
al.; 2013), but also show that the HCM mutational spectrum consists mainly in missense mutations. 
In fact, only ~7% of the identified variants are truncating (frameshift or nonsense SNVs), and they 
map preferentially in MYBPC3 (Bottillo et al.; 2016a). This finding suggests that MYBPC3 
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molecular alterations can be both amino acid substitutions but also loss of function mutations, in 
contrast to the other analyzed loci that resulted mostly affected by missense change. We did not 
observe any strong mutation hot-spot, and only 8/106 nsSNVs recurred in more than one patient. 
In our cohort, sarcomeric loci resulted as the most affected ones and, among them MYBPC3, MYH6 
and MYH7 showed the main proportion of nsSNVs. These data confirm the major role of cardiac 
myosin binding protein C and of myosin heavy chain 7 in hypertrophic cardiomyopathy 
pathogenesis (Millat et al.; 2010; Lopes et al.; 2013), and following the results by Lopes et al. 
(2013) clench myosin heavy chain 6 as one of the most recently established sarcomeric HCM genes. 
Eleven percent of the patients showed only sarcomere nsSNVs, while 20% of cases harbored at 
least one sarcomeric nsSNV with at least a desmosomal one. Moreover we found that 14% of the 
HCM patients displayed at least one desmosomal nsSNV but no other sarcomere change. Such a 
direct association of desmosomal alterations with HCM has not been described to date (Bottillo et 
al.; 2016a). Four/40 patients resulted negative to the next generation analysis about 62 sarcomeric 
and non-sarcomeric genes. To date, there are not any strong algorithms enable to detect large 
duplications/deletions using NGS data. Genomic alterations in genes commonly associated with 
hypertrophic cardiomyopathy are an infrequent but important genetic cause of HCM in ~2% of 
patients without identified mutations by sequence analysis. 
Therefore, we hypothesized that large deletions or duplications of one or more selected genes could 
occur in our 4-HCM patients in which no mutation was identified by NGS analysis.  
In 2013, Lopes and colleagues analyzed by NGS a large cohort of HCM cases and found that 10% 
of them carried nsSNVs in titin only in association with desmosomal or ion channel variants, but 
not other sarcomere ones. Titin variants have previously been reported in apparently healthy 
patients but we found that 52% of the 44 HCM patients harbored at least one TTN nsSNVs with 
MAF ≤ 0.05. Indeed, high prevalence of titin mutations was also reported by Golbus and colleagues 
who analyzed the ‘1000 Genomes’ cohort. A cumulative frequency of titin indels of 9% was found, 
with just over 5% of the general population having a 18bp in frame deletion in the PEVK region of 
titin (Yamasaki et al.; 2001) (Castro-Ferreira et al.; 2010). It is not to be underestimated the 
regulation of titin by calcium ions. The calcium ion (Ca2+) has a big role as regulator of 
cardiomyocyte distensibility, especially due to the modulation of the interaction between titin and 
the thin filaments. Studies have shown that the PEVK domain in the extensible region of the N2B 
isoform binds to F-actin and that this interaction can contribute to the passive rigidity of 
cardiomyocytes (Yamasaki et al.; 2001) (Castro-Ferreira et al.; 2010). Although Ca2+ alone can not 
interfere with this binding, when this ion binds to protein S100A1 (S100 calcium-binding protein 
A1), which is found at high concentrations in the myocardium, this interaction is inhibited, 
 96 
decreasing the rigidity of the cardiomyocyte. The observation of the increase in rigidity of the 
cardiac muscle in parallel to the decrease in the concentration of Ca2+ during diastole supports this 
mechanism (Yamasaki et al.; 2001) (Castro-Ferreira et al.; 2010). Thus, titin may be an important 
disease gene not only because it causes diseases on its own but it may modify the phenotype of 
mutations in other genes.  
Future study on the TTN changes discovered in our 44 HCM patients, with the employment of 
programs for assessing the possible pathogenicity of these variants, might prove the role of this 
giant protein as a phenotypic modifier in association with rare mutations discovered by the NGS 
panel in the pathogenesis of hypertrophic cardiomyopathy. 
Furthermore, mutations in the filamin C gene (FLNC) have very recently been associated with 
HCM (Valdes-Mas et al.; 2014). Moreover, some of those cases might also have alterations of 
genomic region that were not covered by our NGS panel (i.e. 3'UTR, 5'UTR, ncRNAs). Future 
studies of FLNC and of sequences regulating the cardiomyopathies genes' expression will shed 
some light on rising role of desmosomes in HCM as well as in DCM (Haas et al.; 2015). 
As sarcomere and desmosomes nsSNVs were the major changes associated with HCM, and we 
speculate that the other non-sarcomeric loci might have a modifying effect on HCM phenotype. As 
demonstrated in a recent study, non-sarcomeric variants may indeed influence the disease 
expression, outlining the complexity of HCM genetic basis (Lopes et al.; 2014). Statistical analyses 
performed in our cohort, revealed that not only a higher number of nsSNVs seems to correlate with 
an earlier disease onset, but also that those alterations in genes for Ca2+homeostasis, for K+ and 
Na+ channels, and for cytoskeletal proteins can modulate HCM expression. Ion (Ca2+, Na+ and K+) 
channel variants correlate to an earlier disease onset and to a lower maximal wall thickness, while 
changes in cytoskeletal loci correlate with non-sustained ventricular tachycardia onset and low-
grade diastolic dysfunction. Moreover, sarcomeric nsSNVs were correlated to a lower NYHA class 
(Bottillo et al.; 2016a). A recent study on a large HCM population, reported that the prevalence of 
male sex was lower in sarcomere-positive individuals (Lopes et al.; 2014). We did not replicate this 
finding, and we found a higher proportion of males respect to women in the group of positive 
nsSNVs cases. The comparison of data from familial and sporadic cases generated 3 significant 
correlations: (i) the mean of the maximum wall thickness value of was lower in the sporadic group; 
(ii) non-sustained ventricular tachycardia was correlated with familial cases; (iii) the implantation 
of ICD resulted to be linked to a familial framework. 
We also identified 49 synonymous rare variants that might act as phenotype modifiers. Additional 
studies about their function on mRNA transcription, splicing, transport, translation or modification 
are required for determining their possible non-silent role. 
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Among the 97 identified nsSNVs, a single variant was identified in homozygosity (i.e. ABCC9 
p.V734I in patient 21). Such a variant was already associated to a higher risk of developing
precocious myocardial infarction (Minoretti et al.; 2006), but patient 21 did not show that 
occurrence up to now. 
Including both the non-syndromic and the syndromic cases, 25 out of 62 genes resulted negative to 
the mutation screening. Between them, there were not desmosomal loci, but four sarcomeric ones: 
ACTC1, MYL3, TNNC1 and TNNI3. In line with the present results, previous studies reported a rate 
of heterozygous mutated patients less than 1% for ACTC1 (Olson et al.; 2000), MYL3 (Poetter et 
al.; 1996) and TNNC1 (Landstrom et al.; 2008). TNNI3 alterations are expected in about 5% of 
HCM cases (Hershberger et al.; 2013), but we did not found any mutated patient for this gene. If a 
clear TNNI3 genotype-phenotype association exists, this discordance might be due to a bias in 
patients' selection, but of course additional studies on larger cohorts are needed to investigate this 
observation. 
Between the 25 negative genes, there were 16 loci already associated with hypertrophic or dilated 
cardiomyopathy (ACTC1, ANKRD1, CRYAB, DES, EYA4, GATAD1, LDB3, MYL3, MYLK2, 
MYOZ2, NEXN, PLN, SGCD, TCAP, TNNC1 and TNNI3), 3 with myopathies and neuromuscular 
disorders (EMD, FXN and TAZ), 2 with storage disorders (PRKAG2 and TTR), one with ventricular 
tachycardia (CASQ2), one with arrhythmogenic right ventricular cardiomyopathy (TMEM43), one 
with Noonan syndrome (PTPN11) and one cardiovascular candidate gene (CTF1). Six of the 
negative loci (ANKRD1, CRYAB, CTF1, EMD, EYA4 and FXN) were not included in a recent study 
about NGS analysis of a large cohort of HCM patients (Lopes et al.; 2014). 
Three patients showed syndromic HCM and the NGS analysis allowed the confirmation of their 
clinical diagnosis. Patient 10 was a 60-year-old woman with apparently isolated non-obstructive 
HCM featuring a maximum left ventricular wall thickness of 18 mm. Subsequently, she resulted 
heterozygous carrier of the p.N215S mutation in GLA gene, responsible of the X-linked recessive 
Fabry disease. This mutation was previously associated to a cardiac variant of the disease by Eng et 
al. (1993) and by Davies et al. (1993), and our data confirm this genotype–phenotype association. 
Patient 24 was a 6-year-old girl originally ascertained for the clinical suspect of Cantù syndrome, a 
syndromic form of early-onset HCM also featuring coarse face, hirsutism, persistence of fetal 
circulation, overgrowth of prenatal onset and mild bone dysplasia, which was recently associated 
with specific ABCC9 mutations (van Bon et al.; 2012). Accordingly, we found the recurrent 
heterozygous ABCC9 p.R1154W mutation, which subsequently resulted de novo (Harakalova et al., 
2012; van Bon et al., 2012). Finally, patient 27 showing some intellectual impairment and severe 
cardiac disease requiring heart transplant and limb weakness, harbored the novel p.F151Lfs*32 
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mutation in LAMP2, the gene causing Danon's disease, an X-linked dominant disorder 
predominantly affecting cardiac muscle (Nishino et al.; 2000). According to our meta-analysis of 
published clinical data (summarized in Table 12), the majority (81%) of cases are familial. To date, 
characterization at both the clinical and molecular levels has been reported for 124 Danon patients 
(60 males, 31 females, and 33 cases for which sex has not been reported). 
 
 
Table 12. Clinical features of patient 27 and other 91 additional cases from previous studies (Bottillo et al.; 2016c) 
 
Heart disease is the dominant clinical feature in both males and females affected by Danon disease, 
and it is often associated with conduction disease. Early-onset, severe cases have only occasionally 
been described in females; the onset of cardiac symptoms is usually 10 years later in affected 
women as compared to males. This is typically ascribed to most women expressing a functional 
copy of LAMP2 (haplosufficiency) that is sufficient to protect them even with X-inactivation. 
Accordingly, life expectancy is about 25 years longer, and heart transplantation is performed about 
8 years later in females than in males. The early onset of cardiac symptoms in the present case 
could be accounted by the presence of a truncating mutation, as shown in our analysis of published 
literature. However, only a few female patients carrying LAMP2 mutations with both early and 
severe cardiac disease have been reported to date (Yang et al.; 2005) (Dara et al.; 2011) (Miani et 
al.; 2012) (Hedberg et al.; 2015) (Bottillo et al.; 2016c), and the reasons for this unusual 
phenotypic expression are not completely understood. Oldfords and colleagues (Hedberg et al.; 
2015) evaluated the distribution of LAMP2-deficient cardiac myocytes in hearts from three female 
Danon patients, which were transplanted due to severe cardiomyopathy. They hypothesized that the 
inhomogeneous distribution pattern, rather than the absolute amount of LAMP2-deficient cardiac 
myocytes, is responsible for the severe cardiac involvement in these cases. In our study, we extend 
their results by showing that the uneven, patchy distribution of LAMP2 in cardiomyocytes is 
correlated with the percentage of XCI, being more extensive in the ventricular septum. Moreover, 
we demonstrate a previously unreported finding in Danon cardiomyopathy, that is, the presence of 
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diffuse and severe lumen narrowing of coronary intramural arterioles, with a clear spatial 
relationship with foci of replacement-type fibrosis. This association has been extensively described 
in hypertrophic cardiomyopathy due to mutations in sarcomeric protein genes and is considered the 
morphologic substrate of progressive systolic impairment in hypertrophic cardiomyopathy patients 
due to ischemic myocyte loss (Olivotto et al.; 2015). The presence of diffuse microvascular disease 
could be a determinant for the severe cardiac phenotype in this female patient with DD. Intriguingly, 
the ventricular septum was relatively spared from myocardial scarring, while the left ventricular-
free wall was diffusely affected, resulting in a marked decrease in the wall thickness, which 
mimicked the pattern of asymmetrical septal hypertrophy frequently described in sarcomeric HCM 
(Bottillo et al.; 2016c). Indeed, this case shows overlapping histologic findings with sarcomeric 
HCM, that is, extensive myofiber disarray and microvascular remodeling associated with 
microscarring raising the issues of the differential diagnosis between the two diseases also on 
pathologic examination. 
Finally, the pattern of distribution of myocardial scarring in our case is in line with cardiac 
magnetic resonance findings of late gadolinium enhancement involving the LV free wall and 
sparing the septum, reported in a Danon patient (Piotrowska-Kownacki et al.; 2009), and may be 
helpful in the differential diagnosis between primary hypertrophic cardiomyopathy and Danon 
disease. 
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6. CONCLUSION 
 
Cardiomyopathy refers to an important and heterogeneous group of related diseases of the heart 
muscle in which the myocardium is structurally and functionally abnormal such as hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right or left ventricular 
cardiomyopathy (ARVC/ALVC) and restrictive cardiomyopathy (RCM). The evidence of genetic 
and phenotypic overlap among different cardiomyopathies adds other complexity, often resulting in 
stepwise analysis of multiple disease-specific genes when the diagnosis is not so clear. 
Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder, affecting one of 
every 500 adultsaffects people of both genders and of various racial and ethnic origins. It is a 
primary genetic cardiomyopathy characterized by left ventricular hypertrophy, which is usually 
asymmetric, with greater involvement of the interventricular septum than the left ventricular-free 
wall in the abscence of another systemic or cardiac process. 
Thanks to the employment of next generation sequencing technology in view of the genetic overlap 
between different types of cardiomyopathies, we developed a molecular test suitable for a broad 
series of both non-syndromic and syndromic affected patients. Moreover, despite the large amount 
of data coming out from an NGS protocol, we delineated a prompt informatic pipeline for the 
prioritization of the most likely pathogenetic variants in a clinical context. 
The conducted genotype–phenotype correlations represent a starting point for expanding the present 
results to larger cohorts and for delineating the contribution of each analyzed gene in the onset and 
clinical variability of HCM. In the future indeed, a broad range of molecular causes (i.e. 
desmosomal or other non-sarcomeric alterations) and environmental factors will need to be 
investigated in wider populations of sporadic and familial cases. 
Futhermore we analyzed the same 44 HCM patients for another cutom cardio panel designed to 
analyze coding, intronic junctions and UTR sequences of TTN genes. The discovered titin variants 
might not cause diseases on their own but may modify the phenotype of mutations in other genes. 
These data argue that TTN mutations should not currently be interpreted as disease causing in most 
situations, urge caution in the interpretation of these variants in clinical practice, and support the 
need for the development of functional assays that better assess pathogenicity. 
If correct this would be an important consideration for future genetic testing and study of genotype-
phenotype relationships.  
Therefore we describe the clinical, pathological, and molecular features of a novel LAMP2 
c.453delT mutation in one of our HCM-related disorders patients affected by Danon disease. Our 
findings suggest that several features may contribute to the early and severe cardiac phenotype in 
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female DD patients. The type of mutation may account for the early disease onset, while both the 
inhomogeneous distribution of LAMP2 loss due to zonal inactivation of the X chromosomes and 
the presence of microvascular remodeling may be determinants in the rapid progression to heart 
failure. 
In the context of cardiomyopathies, the characterization of the family mutation helps indeed in 
planning surveillance and early detecting possible complications in close relatives. This also implies 
that relatives discovered without the familial mutation can avoid unnecessary follow-up. 
In conclusion, our results enlarge the mutational spectrum of hypertrophic cardiomyopathy patients 
with the intent of contributing to the definition of a molecular paradigm for explaining the diversity 
clinical spectrum of hypertrophic cardiomyopathy. 
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LIST OF ABBREVIATIONS 
AC  Anelylylcyclase 
AICD Automated Implantable Cardioverter-Defibrillator 
AF  Atrial Fibrillation 
AR  Androgen Receptor  
ARVC  Arrhythmogenic Right Ventricular Cardiomyopathy 
ARVD  Arrhythmogenic Right Ventricular Dysplasia  
ALVC  Arrhythmogenic Left Ventricular Cardiomyopathy 
AMI/NSTEMI Acute Myocardial Infarction Non-ST elevation Myocardial Infarction 
AMP  Activated protein kinase 
ANGII  Angiotensin II 
ASD  Atrial Septal Defect 
ATFB  Atrial Fibrillation 
BMD  Becker Muscular Dysptrophy 
BP  Blood pressure 
BRGDA1  Brugada syndrome 1 
BTHS  Barth syndrome 
CAB  Coronary Bypass 
CaChBl  Calcium channel blocker  
CFCS  Cardiofaciocutaneous syndrome 
CK  Serum creatine kinase 
CMD1M Cardiomyopathy, dilated, 1M 
CMRI  Cardiac magnetic resonance 
CMT2B1  Charcot-Marie-Tooth disease, axonal, type 2b1 
Cond Abn  Conduction abnormalities 
CPVT1  Ventricular Tachicardia, Catecholaminergic Polymorphic, 1 
CPVT2  Ventricular Tachicardia, Catecholaminergic Polymorphic, 2 
CS  Costello syndrome 
CT  Cytoplasmic tail  
CTRCT16  Cataract 16 
CTS1  Carpal Tunnel syndrome 
CV  Cardiovascular 
CVG  Coronary-Ventriculography 
DAD  Deafness, autosomal dominant 
DCM Dilated cardiomyopathy 
DCWHK  Cardiomyopathy, dilated with woolly hair and keratoderma 
Dgn Age  Age at diagnosis 
Diast Dys Diastolic Dysfunction 
DM1  Myotonic dystrophy type 1 
DMD  Duchenne Muscular Dystrophy 
ECC  Excitation-Contraction Coupling 
ECG  Electrocardiogram 
ECG Hyp Electrocardiogram Hypertrophy criteria 
EDMD  Emery-Dreifuss Muscular Dystrophy 
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EF Ejection fraction 
ERT Enzyme replacement therapy  
ET Endothelin 
DD Danon Disease 
emPCR        Emulsion PCR 
Fam His Family History 
FAP Amyloidosis, hereditary transthyretin-related 
FCT Fetal cardiac titin 
Fn3 Fibronectin type 3 
FPLD2 Lypodystrophy, familial partial, 2 
FRDA Friedreich’s ataxia 
GC Guanylylcyclase 
HCM Hypertrophic Cardiomyopathy 
HD Huntington’s disease 
HEM Hemizygosity 
HF Heart Failure 
HGPS Hutchinson-Gilford Progeria 
HMZ Homozygosity 
HOCM Obstructive Cardiomyopathy 
Hpt Hypertension 
HR Heart Rate 
HTX Heart Transplantation 
HTZ Heterozygosity 
ICD Implantable cardioverter-defibrillator 
Ig Immunoglobulin 
IIE Intron identity element 
ISPs Ion Sphere Particles 
IPT Inositol triphosphate 
IVS Interventricular septum 
JMML Juvenile Myelomonocytic Leukemia 
KSS Kearns–Sayre syndrome 
LAFB Left Anterior Fascicular Block 
LBBB Left Bundle Branch Block 
LGMD Muscular Dystrophy, Limb 
LQT Long QT syndrome 
LV Left Ventricle  
LVDD left ventricular diastolic dysfunction  
LVEF Left Ventricular Ejection Fraction 
LVH Left ventricular hypertrophy 
LVM Left Ventricular Mass  
LVNC Left Ventricular Noncompaction 
LVOT Left ventricular outflow tract  
LVOTO Left ventricular outflow tract obstruction 
MADA Mandibulo acral dysplasia 
MAF Minor Allele Frequency 
MAPK Mitogen-activated protein kinase 
MARPs Muscle Ankyrin Repeat Proteins  
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MELAS  Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes 
METCDS  Metachondromatosis  
MHC  Myosin Heavy Chain 
MFM  Myopathy, myofibrillar 
MPD1  Myopathy, distal 
MPDT  Myopathy, distal Tateyama Type 
mtDNA Mitochondrial DNA 
MURF  Muscle specific ring finger protein 
MWT  Maximal Wall Thickness  
Myct  Myectomy 
NE  Not evaluated 
NGS  Next Generation Sequencing  
nPath Non-Pathogenic  
NO  Nitric oxide 
NS  Noonan syndrome 
NS1  Noonan syndrome 1 
nsSNVs       non-synonimus single nucleotide variants 
NSVT  Non-Sustained Ventricular Tachycardia 
NYHA  New York Heart Association functional class 
PAS  Periodic Acid–Schiff-positive granules  
Path  Pathogenic 
PCR  Polymerase Chain Reaction 
PFHB1A  Progressive familial heart block, type Ia 
Pi  Phosphate 
PMK  Pacemaker 
PnPath  probably-non-pathogenic 
PPath  probably-pathogenic  
PPKS2  Keratosis Palmoplantaris Striata II 
PSVT  Paroxysmal Supraventricular Tachycardia 
PT  Patients 
RBBB  Right Bundle Branch Block 
RCM  Restrictive cardiomyopathy  
RMD  Rippling muscle disease 
RMSD  Root-mean-square deviation  
RV  Right Ventricle  
SA  Sinus Arrest 
SAM  Systolic anterior movement  
sANK-1      Small ankyrin-1  
SAR  Supraventricular Arrhythmias  
SCD  Sudden Cardiac Death  
SCPNK  Scapuloperonal syndrome, neurogenic kaeser type 
SFWHS  Skin fragility-woolly hair syndrome 
SPMM  Scapuloperoneal syndrome, myopathic type 
SR  Sarcoplasmic reticulum  
SSS  Sick sinus syndrome, autosomal recessive 
Sync/Presync Syncope/Presyncope 
TDI  Doppler imaging  
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Thor pn Thoracic pain 
TM Transmembrane region 
TS Target Sequencing 
UNK Unknown 
UTR Untraslated region 
VF1 Ventricular fibrillation during myocardial infarction, susceptibility to 
VO2 Ventricular maximal oxygen uptake  
VT Ventricular tachycardia  
VUS Variants of uncertain significance 
WPW Wolff-Parkinson-White Syndrome 
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